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Podocytes are highly specialized epithelial cells with complex morphology which
cover the outer surface of the glomerular basement membrane and form the final
barrier to protein loss during glomerular filtration. Podocyte injury is characterised
by the presence of proteinuria, even without any detectable morphological changes,
and there is compelling evidence that further damage to podocytes is central to the
development of focal and complete glomerulosclerosis and development of chronic
renal failure. It is an attractive idea that podocyturia could be a prognostic marker
enabling high-risk patients to be targeted for specific therapy. Detection of urinary
podocytes by immunofluorescence has indeed been reported to reflect
glomerulonephritis activity in both animals and man, but most publications
concerning patients are from a single group.
Aims
1. To test the hypothesis that it would be prognostically useful to be able to
identify podocytes in urine of patients with proteinuric renal disease, and that
a reverse transcriptase polymerase chain reaction (RT-PCR) method would be
an efficient and clinically applicable way to do this.
2. To create an animal model in which a graded podocyte injury could be
induced, and examined alone or in combination with other pathology. This
would be useful to test the hypothesis that treatment that protects the
podocyte would ameliorate the disease.
Materials and Methods
1. Total RNA was extracted from urine samples (20 ml each) of 70 proteinuric
(urine protein >+++) renal patients at the renal outpatient department of
Edinburgh Royal Infirmary. This was followed by RT-PCR for nephrin,
podocalyxin (podocyte specific mRNAs) and p-actin (positive control)
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cDNAs. Immunofluorescence was conducted on urine samples of 100
patients with similar criteria using an anti-synaptopodin antibody (podocyte
antibody).
2. Induction of specific podocyte injury with diphtheria toxin (DT) in a
transgenic mice expressing human diphtheria toxin receptor (hDTR) on
podocytes. Mice DTR is normally resistant to the effects of DT. These
transgenic mice were generated by male pronuclear microinjection of murine
fertilized ova with the plasmid (pIN); a construct contains murine nephrin
promoter (podocyte promoter) and hDTR gene which is human Heparin
Binding-Epidermal Growth Factor cDNA (hHB-EGF cDNA).
Results
1. All of the 70 urine samples were negative for podocyte protein mRNAs by
RT-PCR, although many samples gave positive p-actin results, and control
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examined by immunofluorescence, only one (1%) gave a positive result. The
technique was tested with human cultured podocytes and found to detect 10-
20% of the actual number of podocytes in urine, and a similar proportion of
control cells.
2. Two trials of male pronuclear microinjection of fertilized murine ova with
podocyte construct were undertaken. The first microinjection trial was
unsuccessful but four hDTR transgenic founders (tg21.1, tg47.1, tg57.1,
tg65.1) were established with the second round of microinjections. They gave
identical results in two genotyping PCRs. These founders have shown the
capability of passing the transgene to their phase 1 offspring.
Discussion
1. The results of urine examination for podocytes contrast with those reported
by Hara and colleagues (1995 and 1998). This could be partly because they
examined selected high risk patients, but it may also be relevant that
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podocalyxin can be found on platelets and elsewhere. I looked at a clinically
relevant population using clinically applicable tests. I did not find evidence
that urinary podocyte excretion commonly occurs at detectable levels in these
patients.
2. The tg21.1 and tg57.1 founders produced relatively adequate offspring at
phase 1. So, the plan was to stop parents from breeding and preserve them,
test some of their phase 1 offspring kidneys with anti-hEGF antibody to look
for the expression of hDTR on podocytes and set the rest of their offspring to
breed. The parents of tg47.1 and tg65.1 did not produce adequate offspring
for anti-hEGF staining, so they are and their phase 1 offspring continue to
active breed.
Conclusions
1. Looking for urinary podocytes is not a clinically useful technique in patients
with proteinuria.
x
2. Podocyte construct (pIN) has proved its validity by generating four transgenic
founders by male pronuclear microinjection and furthermore, all of them have
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This thesis concerns the podocyte in proteinuric renal diseases. In the Introduction,
first there is a brief description of the human diseases in which podocyte injury seem
to be central in their pathogenesis. Second, podocytes origin and development are
discussed because the importance of the limited proliferation capacity of these cells
after their injury in glomerular diseases. Third, podocytes structure and function are
covered because they form the final barrier of protein loss during glomerular
filtration. Fourth, animal models and mechanisms of podocytes injury are reviewed
with their relation to clinical practice, as well as the evidence behind urinary
podocyte in glomerular diseases. Finally, at the end of this chapter the aims of this
project are presented.
The podocyte is one of four cell types that are found in the glomerulus; endothelial
cells, mesangial cells, parietal epithelial cells and visceral epithelial cells
(podocytes). The endothelial cells cover the inner aspects of the capillary loops;
mesangial cells and mesangial matrix occupy the axial region of the capillary
convolute and parietal epithelial cells cover the inner aspect of Bowman's capsule
(figure 1.1).
Podocytes are highly specialized and terminally differentiated epithelial cells with
complex morphology which cover the outer surface of the glomerular basement
membrane (GBM) and form the final barrier to protein loss during glomerular
filtration process (figure 1.1).
Diseases causing proteinuria are associated with podocytes
The evidence for a central role of podocyte injury in the development of glomerular
disease is substantial. The early events of podocyte injury are characterised by the
presence of proteinuria even without any detectable morphological changes, and
further damage to podocytes is central to the development of focal and complete
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Figure 1.1. The Structure of normal glomerulus
(Feehally and Johnson, 2000)
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Minimal change disease and focal segmental glomerulosclerosis
Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are
the cause of nephrotic syndrome in about 90% of children aged less than 10 years,
about 50-70% of older children, and 20-35% of adults. They are considered together
because both are characterised by a diffuse capillary wall defect in the absence of
immune deposits, have common clinical features, and are treated in a similar way.
MCD is defined by the absence of histological glomerular changes apart from
podocyte foot process effacement in patients presenting with steroid responsive
nephrotic syndrome.
FSGS was first described in 1957 and is now a common glomerular lesion in patients
with nephrotic and non-nephrotic range proteinuria. It accounts for 10-30% of
chronic glomerulonephritis. FSGS is defined histologically by segmental capillary
obliteration with increased mesangial matrix deposition, intracapillary hyaline
denosits. nodocvtes proliferation fin some variants! and focal adhesions of caoillarv
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tuft to Bowman's capsule.
Primary FSGS (idiopathic) is a common disease in young patients with nephrotic
syndrome. Secondary FSGS is a mixture of conditions in which there are segmental
scars, and as discussed later progression of these diseases may be related to podocyte
injury.
Membranous nephropathy
Membranous nephropathy (MN) is the main cause of nephrotic syndrome in adults. It
is a glomerular disease characterised by the thickening of the glomerular capillary
wall without any increase in the mesangial cellularity or expansion, and immune
deposits (IgG and complements components) development on the subepithelial
surface of the glomerular capillary wall. The deposition of these immune complexes
leads to the increase of glomerular permeability to proteins and development of
nephrotic syndrome. MN is associated commonly with systemic lupus
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erythematosus, diabetes mellitus, hepatitis B infection, drugs (gold, penicillamine
and non-steroidal anti-inflammatory agents) and malignancy.
Experimental evidence (below, pathology of podocytes) also points to a central role
of podocytes in the pathogenesis ofMCD, FSGS and MN.
Genetic disorders of podocytes
Mutations of podocyte proteins genes cause inherited proteinuric diseases. Nephrin
gene (NPHS1) mutation leads to the development of Finnish type nephrotic
syndrome (Kestila et al., 1998). CD2 associated protein (CD2AP) gene mutation
leads to congenital nephrotic syndrome (Shih et al., 1999). Podocin gene (NPHS2)
mutation leads to the development of autosomal recessive FSGS (Boute et al., 2000).
a-Actinin-4 gene (ACTN-4) mutation leads to the development of autosomal
dominant FSGS (Kaplan et al., 2000). Wilm's tumour suppressor gene (WT1)
mutation leads to primary steroid-resistant FSGS (Denamur et al., 2000).
Origin and development of podocytes
The epithelial cells of most organs of the body form by an extension of a pre-existing
epithelial sheet during embryogenesis by a process known as branching
morphogenesis. The epithelial cells of the ureter and collecting ducts form by such a
process (Grobstein, 1953; Saxen, 1987). The epithelial cells of tubules and within the
glomeruli are formed by direct conversion of mesenchyme to epithelium (Saxen,
1987).
Human metanephric development begins during the fifth week of gestation
(figure 1.2). It is characterised by aggregation of nephrogenic mesenchyme opposite
to branches of the ureteral bud (vesicle stage), formation of the primitive S body
consisting of presumptive glomerular and tubular epithelium, followed sequentially
by capillary ingrowth, GBM formation, and differentiation of glomerular parietal,
visceral and tubular epithelium. Development proceeds in a centrifugal fashion as
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Figure 1.2. Scheme of differentiation of individual nephric units.
The epithelial ureter bud will branch into the mesenchyme as a result of an
interaction between the ureter and mesenchyme (indicated by arrows). The stage at
the top right shows the different cell lineages that begin to emerge once the ureter
epithelium has branched once into the mesenchyme; (1) ureter epithelium, (2) blood
vessels, (3) uncondensed mesenchyme that will differentiate into stroma, (4)
condensed mesenchyme that will convert into epithelium. The condensed
mesenchyme soon develops into a comma-shaped and S-shaped epithelium, and
proximal and distal tubules can be distinguished. The glomerulus has begun to form
at S-shaped stage. Blood vessels can be seen within the developing glomerulus at the
comma shaped stage (Sorokin and Ekblom, 1992).
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In mouse at eleven days of gestation the ureter begins to grow into the metanephric
mesenchyme, initiating epithelial tube formation. In turn mesenchyme stimulates
further ingrowth and branching of the ureter (figure. 1.2). It is at the branching tips of
the ureter that mesenchyme is induced to form epithelium (Sorokin and Ekblom,
1992).
Epithelial cell development can be stimulated in vivo by the epithelium of the ureter
(Sorokin and Ekblom, 1992) and in vitro by a spinal cord (Saxen et al., 1983).
Nephron segmentation in vitro into Bowman's capsule, glomerular podocytes, and
distal and proximal tubules is similar to that occurs in vivo (Ekblom et al., 1981).
Saxen (1987) reported that glomerular (and podocyte) development can be divided
into four stages (renal vesicle, S-shaped body stage, capillary loop stage and
maturing glomeruli). The early stages of podocyte development are renal vesicle
stage and S-shaped body stage; the later stages represent the more advanced stages of
podocyte maturation (Mundel and Kriz, 1995).
Immature cells (vesicle and S-shaped body stages) have high rate of multiplication;
this is related to the expression of the proliferating cell nuclear antigen (PCNA) in
these cells. This is not expressed by capillary loop stage cells (Nagata et al., 1993).
Mitotic figures are frequently seen in the nephrogenic vesicle and S-shaped bodies
(Nagata et al., 1993). Developing podocytes lose their mitotic activity once they
reach capillary loop stage of their development (Nagata et al., 1993; Mundel and
Kriz, 1995).
During S-shaped body stage the occluding junctions appear at the apical surface of
the developing podocytes. These occluding junctions migrate from the apex to the
base. Initially broad epithelial processes cover the whole outer aspect of the
developing basement membrane. After junctional migration interdigitation of
epithelial processes is seen, and the processes are joined by focal occluding
junctions. With more elaborate interdigitation, fewer intercellular spaces are closed
by occluding junctions. The junctions become less and less extensive, and normal slit
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architecture with foot processes bridged by slit membranes start to form (Reeves et
al., 1978; Reeves et al., 1980). When developing podocytes enter the capillary loop
stage their complex architecture starts to establish. This includes the appearance of
foot processes and formation of slit diaphragms (Mundel and Kriz, 1995).
A number of proteins that are podocyte-specific in adult kidney start to appear about
S-shaped stage of glomerulogenesis:
• Schnabel and associates (1989) examined the appearance and distribution of
podocalyxin on the podocytes during glomerulogenesis. They found that
podocalyxin appeared first on the apical surface of the developing podocytes
of the S-shaped body above the level of occluding junctions. Podocalyxin
becomes detectable during S-shaped body stage of glomerular development
on the apical and lateral surfaces of podocytes, shortly after the migration of
occluding junctions (Reeves et al., 1978).
• The foot processes of podocytes are attached together by slit diaphragm. One
of the components of this structure is zonula occludensl (ZO-1), a protein
that is specific for tight junctions. It appears during S-shaped body stage of
glomerular development. It was present when the apical junctional complexes
between presumptive podocytes are composed of typical tight and adhering
junctions, they migrate together along the lateral cell surface, disappeared and
replaced by slit diaphragms (Schnabel et al., 1990).
• Mundlos and colleagues (1993) demonstrated that the expression of Wilm's
tumour suppressor gene (WT1) protein occurs during S-shaped body stage of
glomerulogenesis and reachs its highest level in this stage also.
During the maturing glomeruli stage, the glomeruli resemble those in adult kidneys
but their diameter is smaller in rats (Abrahamson, 1991). Double basement
membranes (subepithelial and subendothelial), which appear during earlier stages of
development, disappear at this stage (Senior et al., 1988; Laurie et al., 1989).
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Basement membrane laminin synthesis is now mostly performed by mature
podocytes (Abrahamson and Perry, 1986). At capillary loops expansion areas where
podocytes foot processes formation and interdigitation becomes more active, loops of
GBM localize at subepithelial areas (Abrahamson, 1986; Abrahamson, 1987).
Replication of podocytes
It is often suggested that podocytes are post-mitotic cells, and that once injured they
can not replicate to compensate the dead cells, but as pointed by Nagata and
collaborators (1993) no studies have demonstrated that unequivocally. Podocytes
have a differentiated cell shape and are found in unique position. Their cell bodies
are floating within the filtrate in Bowman's capsule and attached to glomerular
capillaries by the foot processes. This arrangement seems to be incompatible with
cell replication (Nagata and Kriz, 1992).
Several studies have shown that podocytes do not replicate during postnatal normal
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growth (Pabst and Sterzel, 1983; Rasch and Norgaard, 1983; Fries et al., 1989;
Nagata and Kriz, 1992).
Nagata and Kriz (1992) analyzed podocytes lesion in young rats after
uninephrectomy. They reported that with overall glomerular growth after
uninephrectomy, a pronounced hypertrophy of podocytes was observed but the mean
number of podocytes per glomerulus did not change. They assumed that podocytes
can not sustain the same degree of growth as the glomerular tuft as a whole, and
podocyte hypertrophy is soon followed by maladaptive changes which end with cell
destruction.
It has been suggested that the occasional appearance of mitotic figures (Pabst and
Sterzel, 1983; Rasch and Norgaard, 1983; Schwartz and Lewis, 1985) may be
explained by incomplete mitosis leading to binucleated or multinucleated cells. A
study by Shankland and co-workers (1997) showed that the low proliferative
capacity of podocytes in response to an injury may be due to an increase in the
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expression of a specific cyclin kinase inhibitors p21 and p27 which block the
important regulatory role of cyclins in cell proliferation.
Other studies have shown that although podocytes can undergo mitosis but not
complete cell division during postnatal life or under experimental and pathological
conditions, collapsing glomerulopathies including HIV-associated nephropathy and
idiopathic collapsing glomerulopathy were exceptions to this rule (Barisoni et al.,
1999; Barisoni et al., 2000). They demonstrated that podocytes de-differentiate, as
reflected by loss of maturity markers such as synaptopodin. Podocyte proliferation
leads to pseudocrescent formation and compression of glomerular tuft (Barisoni et
al., 2000).
Kriz and associates (1994c) demonstrated that podocytes under certain stimuli can
re-enter the cell cycle and undergo mitosis but can not complete cell division. They
examined the effects of the fibroblast growth factor 2 (FGF-2) on the podocytes and
observed the appearance of binucleated or multinucleated cells and mitotic figures.
These cells exhibited degeneration changes including cell body attenuation,
extensive pseudocysts formation, foot processes fusion and local detachment from
the GBM. They concluded that podocytes can enter mitosis but can not complete cell
division.
Podocytes failure to complete cell division appears to be of a critical importance for
chronic renal failure development. Their inadequate proliferative response following
an injury may contribute to the development of progressive glomerulosclerosis in
different glomerular diseases (Kriz et al., 1994a; Shankland et al., 1997).
On the other hand urinary podocytes from rats with experimental membranous
nephropathy (Petermann et al., 2003) and experimental diabetic nephropathy
(Petermann et al., 2004) can be grown, replicate and increase in number in tissue
culture.
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It can be seen that differentiated podocytes can undergo mitosis but not complete cell
division and in contrast to that, de-differentiated podocytes can proliferate.
Structure of podocytes
The GBM provides the primary structural support for the glomerular tuft. The basic
unit of glomerular tuft is a single capillary. Endothelial and mesangial cells are
located inside the GBM and podocytes are attached to its outer aspect. (Mundel and
Kriz, 1995). Podocytes are highly differentiated cells. They can be divided into three
structurally and functionally different parts: cell body, major processes and foot
processes. Cell bodies and major processes are not attached directly to the GBM, but
float freely in the filtrate in Bowman's space, leaving a sub-cell body space between
the cell body and the foot processes (figure 1.3). From the cell body major processes
arise directly or after additional branching, split into foot processes. The foot
processes will form a characteristic interdigitating pattern with foot processes of
neighbouring cells (figure 1.4), leaving in between the filtration slits (Mundel and
Kriz, 1995; Kriz ct al., 1998a).
Podocytes have a large nucleus and prominent nucleolus (figure 1.3). Their cell body
contains a well-developed Golgi system, abundant rough and smooth endoplasmic
reticulum, prominent lysosomes, and many mitochondria. The well-developed
endoplasmic reticulum and Golgi apparatus reflect a high capacity for protein
synthesis. They also contain endocytotic vesicles and multivesicular bodies which
suggest strong endocytotic activity (Mundel and Kriz, 1995; Kriz et al., 1998a).
Podocytes have a complex shape; this is primarily related to their well-developed
cytoskeleton which maintains also podocytes processes (Kriz et al., 1998a).
Drenckhahn and Franke (1988) found that microtubules and intermediate filaments,
such as vimentin and desmin, dominate in the cell body and primary processes as
well the foot processes. This system is composed of actin, myosin II, a-actin, talin,
and vinculin.
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Microtubule-associated protein 3 (MAP 3), is a heat stable protein. It is distributed in
many tissues and MAP 3 containing cells appeared to have in common a symmetric
morphology with long processes that need structural support. In kidney MAP 3 is
limited to podocytes and associated with microtubules and intermediate filaments but
not with microfilaments (Huber and Matus, 1990). Abundant amounts of
microfilaments are located in the foot processes. It has been reported that a complete
microfilament-based contractile apparatus is present in microtubule-associated
protein 4 (MAP 4), and found to be associated with the prominent bundles of
microtubules in the large processes (Parysek et al., 1984).
The microfilaments loop-shaped bundles, with their limbs run in the longitudinal axis
of the foot processes. The bends of these loops are located centrally at the transition
to the primary processes, and are probably connected to the microtubules by another
microtubule associated protein, namely x (tau), which is located at those sites
(Sanden et al., 1995).
Kriz and colleagues (1994d) demonstrated that, peripherally, the actin bundles
appear to anchor in the dense cytoplasm associated with the basal cell membrane of
podocytes, the sole plates of foot processes. Adler (1992), Cybulsky and
collaborators (1992) reported that sole plates of podocyte foot processes anchoring to
the GBM by a3[31-integrin. Integrins interact with the actin cytoskeleton via talin
and vinculin within the dense cytoplasm of the sole plates (Kriz et al., 1998a).
Podocytes are polarized epithelial cells with luminal and abluminal membrane
domains. The border between the abluminal and luminal membranes is delineated by
the slit diaphragm (Mundel and Kriz, 1995; Kriz et al., 1998a). The abluminal
domain is completely embedded into the GBM
The luminal membrane of podocytes contains several specialized membrane
proteins; which some of them have been used as a podocyte identification markers as
described below; including the complement receptor C3b (shin et al., 1977), the
gp330/megalin (Kerjaschki and Farquhar, 1983), the human equivalent of
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Figure 1.3. Peripheral glomerular area.
Four capillary loops (c) are seen with a podocyte in the centre. Podocyte cell bodies
are connected to the capillary wall by their cell processes, which establish the
interdigitating foot process pattern on the outer surface of the GBM. Near the
nucleus with a prominent nucleolus, a characteristic membrane bound inclusion body
(asterix) is seen (Mundel and Kriz, 1995).
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Figure 1.4. Podocyte cell architecture.
Large cell bodies are seen that are fixed to the capillaries by their major processes.
Foot processes arise from the major processes and form the characteristic
interdigitating pattern with the foot processes of a neighbouring cell, leaving in
between the filtration slits (Mundel and Kriz, 1995).
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podocalyxin (Kerjaschki et al., 1986), dipeptidyl peptidase IV (Natori et al., 1987),
the endothelial and podocyte 1 antigen (EnPo 1 antigen) (Kloth et al., 1992), The
glomerular epithelial protein 1 (GLEPP1) (Thomas et al., 1994), the Alzheimer
amyloid precursor protein (Beer et al., 1995), and a 43 KD transmembrane protein
(Breiteneder et al., 1995).
On the luminal surface of podocytes is a well-developed glycocalyx which is
composed of sialoglycoproteins. Kerjaschki and associates (1984), Huang and
Langlois (1985) reported that podocalyxin and podoendin respectively are part of
these sialoglycoproteins. Mendrick and Rennke (1988) showed that sialoglycoprotein
115/107 KD (SGP 115/107) is part of the sialoglycoproteins on the luminal surface
of podocytes.
Cholesterol is present in the luminal podocytes membrane. Orci and co-workers
(1982) believed that cholesterol has an important role in the stability of podocytes
shape, and its complexes link the cytoskeletal components to the cell membrane.
Filtration slits
The filtration slits are the sites of fluid flow between the podocytes. The slit
diaphragm which is the principal filtration barrier to plasma proteins has a
continuous junctional band, 300-500 A wide, present in all filtration slits, and formed
in podocytes foot processes. It was proposed that, the slit diaphragm has a zipper-like
structure with alternating periodic cross bridges extending from the podocyte plasma
membrane to a central filament which run parallel to and equidistant from the cell
membranes. The dimension and spacing of the cross bridges defined a uniform
population of a rectangular slits approximately 40 by 140 A in cross section and 70 A
in length. The total area of the slits is 2-3% of the total surface area of the glomerular
capillaries (Rodewald and Kamovsky, 1974; Furukawa et al., 1991).
Wartiovaara and colleagues (2004) reported using electron tomography that, the slit
diaphragm is a uniformly wide organised network of winding strands. The complex
network contains a class of 35 nm long cross strands which border lateral pores
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smaller than albumin and stains for nephrin. They also reported that, patients with
Finnish type nephrotic syndrome and nephrin knockout mice have narrow filtration
slits lacking the slit diaphragm and the 35 nm strands. These results suggested an
important role of nephrin in the structure of slit diaphragm and its pores.
Nephrin was the first protein to be localized to the slit diaphragm area (Holthofer et
al., 1999; Holzman et al., 1999). It is a transmembrane protein with structural and
signalling functions. It associates intracellularly with podocin (Roselli et al., 2002)
and CD2AP (Shin et al., 2001). Other proteins localized at the slit diaphragm area
include the tight junction protein ZO-1 (Schnabel et al., 1990), a, p, and y catenin
(Reiser et al., 2000), FAT which is a member of the cadherin superfamily (Inoue et
al., 2001), and P-cadherin (Reiser et al., 2000).
Function of podocytes
Podocytes have many functions including GBM turnover, maintenance of the
filtration barrier, Capillary tuft support, and regulation of glomerular filtration.
The GBM is located between the endothelial cells and the podocytes. It usually
thought that the GBM primarily is derived from the epithelium. Podocytes have long
been known to synthesize type IV collagen (Walker, 1973). However, endothelial
cells express (Foidart and Reddi, 1980; Foidart et al., 1980) and can under culture
conditions, synthesized basement membrane (Jaffe et al., 1976). Sariola and
colleagues (1984) demonstrated that podocytes and glomerular endothelial cells
contribute to the formation of GBM. Lee and collaborators (1993) found that the
mesangium has a role in the synthesis of GBM. However from an in vitro model
lacking endothelial and mesangial cells, podocytes alone are able to synthesize a
complete basement membrane (Bernstein et al., 1981; Bonadio et al., 1984).
The protein components of the GBM synthesized by the podocytes include type IV
collagen (Courtoy et al., 1982), heparan sulphate proteoglycan (Stow et al., 1989),
laminin (Abrahamson, 1985; St John and Abrahamson, 2001), fibronectin (Courtoy
et al., 1982), entactin (Bender et al., 1981), and syndecan (Vainio et al., 1989).
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The filtration slits are very permeable to water but prevent passage of most serum
albumin and larger plasma proteins. The filtration barrier consists of the fenestrated
endothelium, the GBM, and the podocytes foot processes with the interposed slit
membrane (figure 1.5). The filtration route is extracellular and the filtrate passes
through the endothelial fenestrate, across the GBM, and through the slit diaphragms
of the filtration slits. Charge, size, and shape determine the specific permeability of a
macromolecule. It has been suggested that intrinsic negative charges which prevent
protein loss are present in the GBM (Rennke et al., 1975), but Daniels (1994) found
that the restriction in albumin permeability due to glomerular charge requires the
presence of glomerular cells. Other studies suggest that the component responsible
for size selectivity is the slit membrane, and it is responsible for a half of the
hydraulic resistance while the GBM is responsible for the other half (Daniels et al.,
1992; Drumond and Deen, 1994; Edwards et al., 1997a; Edwards et al., 1997b).
Podocytes and mesangium have an important role in the structural support of the
glomerular capillaries. They stabilize the folding pattern of the glomerular tuft and
then the architecture of the capillaries. Kriz and co-workers (1994b) demonstrated
that podocytes can provide the stabilizing function alone without the mesangium.
Podocytes also counterbalance the expanding force on the capillary wall exerted by
the transmural pressure gradient.
Kriz and collaborators (1998a) explained the cytoskeletal organization of the
podocytes processes and their relevance to the support function. Firstly, podocytes
interconnect neighbouring capillaries, thereby maintaining the folding pattern of the
glomerular tuft (Mundel and Kriz, 1995). Podocytes frequently fill the narrow angles
between neighbouring capillaries by large cell processes, thereby fixing opposite
parts of the GBM onto one another. The podocytes processes filling these angles
contain microfilaments, and are sites of the synaptopodin accumulation (Mundel et
al., 1991). The relevance in maintaining these angles is seen after total mesangial
dissolution (Bagchus et al., 1986). Even after total mesangiolysis, those angles are
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Figure 1.5. The composition of the filtration barrier.
The glomerular filter consists of three components: fenestrated endothelium, GBM,
and podocyte foot processes with the interposed slit membrane (Mundel and Kriz,
1995).
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maintained and stabilizing the folding pattern of the GBM (Kriz et al., 1995a).
Secondly, podocytes are attached by foot processes to the external surface of GBM
and act as numerous, small stabilizing patches on the GBM, counteracting locally the
elastic distension of the GBM.
Glomerular filtration is determined by the transmural pressure gradient and the
ultrafiltration coefficient (glomerular filtration rate = transmural pressure gradient X
ultrafiltration coefficient). The ultrafiltration coefficient is the product of the
hydraulic permeability and filtration area. Dworkin and Brenner (1992) believe that
the regulation of ultrafiltration coefficient occurs through changes in filtration area
due to an action of the mesangium, but several other studies do not support this
assumption (Sakai and Kriz, 1987; Anderson et al., 1989; Denton et al., 1992).
The role of podocytes in ultrafiltration coefficient regulation is not fully clear.
Andrews (1988) reported that the filtration slit area is responsible for the changes of
ultrafiltration coefficient and this was supported by the correlation of ultrafiltration
coefficient reduction with decrease in total filtration slit length in membranous and
minimal change nephropathies (Drumond et al., 1994).
Podocytes may regulate ultrafiltration coefficient by a dynamic function and this is
supported by the presence of many vasoactive substances receptors on the podocytes
and they include: atrial natriuretic peptide (Yamamoto et al., 1994; Zhao et al.,
1994), bradykinin (Pavenstadt et al., 1992; Ardaillou et al., 1996), nitric oxide
(Mundel et al., 1995), angiotensin II (Yamada et al., 1990; Shake et al., 1992;
Sharma et al., 1992; Gloy et al., 1997; Henger et al., 1997), parathyroid hormone and
parathyroid hormone-related peptide (Lee et al., 1996; Massfelder et al., 1996), and
acetylcholine (Lebrun et al., 1992).
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Pathology of podocytes
Models and mechanisms of podocyte injury
There are a number of experimental models of podocyte injury with observed
anatomical and functional changes which strongly suggest that podocyte injury is
important.
Puromycin aminonucleoside nephrosis (PAN) is a model of minimal change
nephropathy and FSGS. The injection of PAN leads to podocyte foot processes
effacement and development of proteinuria (Inokuchi et al., 1996) which progresses
to focal glomerulosclerosis (Diamond and Karnovsky., 1986). Expression of
a-actinin which precedes foot processes effacement increased in podocytes in PAN
(Smoyer et al., 1997). An increase in the expression of heparanase which mediates
loss of glomerular charge selectivity has been reported in PAN (Levidiotis et al.,
2001). Upregulation of heparin-binding epidermal growth factor-like growth factor
has been found in PAN (Paizis et al., 1999), and the injection of a monoclonal
antibody to it was reported to be followed by an increase in the PAN-induced
proteinuria and decrease in podocyte adhesion to laminin and fibronectin, suggesting
the epidermal growth factor-like growth factor has a role in podocytes adhesion
(Khong et al., 2000). PAN-induced proteinuria is associated with downregulation of
nephrin mRNA and protein expression (Khong et al., 2000), decreased expression of
podoplanin (Breiteneder et al., 1997) and disruption of podocalyxin-erizn complexes
(Takeda et al., 2001).
Protamine sulphate (PS) injection causes podocyte changes similar to those occur in
PAN nephropathy (Andrews, 1975). PS nephropathy is associated with an increase in
the expression of podocytes phosphotyrosine and the newly phospohrylated proteins
are concentrated along newly formed tight junctions and basal membrane of the foot
processes. ZO-1 was found to be a target of tyrosine phosphorylation (Kurihara et al.,
1992). The effect of PS on podocytes can be controlled by tyrosine phosphatases
(Reiser et al., 2000). PS nephropathy is also associated with processes retraction, cell
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rounding and loss of actin filament bundles (Reiser et al., 2000). PS causes an
• • 2+
increase in [Ca ]i in podocytes which is not completely reversible leading to the
suggestion that PS induces an impairment of [Ca2+]i regulation (Rudiger et al., 1999).
This was supported by the finding that perfusion of kidneys with PS nephropathy
with a low extracellular Ca2+ solution lead to 50% reduction in podocytes damage
(Kerjaschki., 1978).
Complement activation is a crucial step in the induction of complement-mediated
podocyte injury and development of proteinuria. Depletion of complement
completely inhibits proteinuria (Cybulsky et al., 1986; Savin et al., 1994). Active
Heymann nephritis (AHN) is a model of human membranous nephropathy which
was developed in rats by immunising them with fraction 1A (a crude renal tubular
preparation). This immunisation induced the production of IgG autoantibodies after
the formation of large subepithelial immune deposits which include IgG, C3, and
membrane attack components (C5b-9) of complement (Heymann et al., 1967;
Kerjaschki and Neale, 1996). Most of the animals developed proteinuria within 8
weeks of immunization. The target autoantigen of AHN is a transmembrane renal
glycoprotein named megalin. Passive Heymann nephritis (PHN) can be induced by
injecting a heterologous antibody against rat megalin or fraction 1A into rat, so
unlike AHN this is not an autoimmune disease. Progressive staining of heterologous
IgG in the subepithelial immune deposits is associated with podocyte foot process
effacement. C3 and C5b-9 membrane attack complex are also present in distribution
similar to heterologous IgG, which suggest that IgG in the immune complexes may
activate complement (Kerjaschki and Neale, 1996).
Fibroblast growth factor-2 (FGF-2) has a role in the regulation of basic functions of
podocytes. Podocytes from FGF-2 knock-out mice grow tightly one to another, they
have actin disorganization, decreased expression of synaptopodin and WT1,
inhibition of their mesenchymal differentiation and abnormal ZO-1 expression
(Davidson et al., 2001). Long term treatment of rats with FGF-2 lead to the
development of albuminuria, podocyte injury, FSGS and chronic renal failure.
Mitotic figures have been observed in podocytes of these rats without real cell
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division and because of that it has been suggested that FGF-2 stimulate podocytes to
undergo mitosis (Kriz et al., 1995b).
The reactive oxygen product hydrogen peroxide (H202) is a cellular injury mediator
and acts directly or indirectly as a source of hypochloride, which is formed in the
presence of chloride and myeloperoxidase, an enzyme secreted by
polymorphonuclear white blood cells (Johnson et al., 1994). In vivo investigation of
H202 glomerular toxicity has shown that its intra-arterial injection leads to
derangement in glomerular permselectivity. H202 induced proteinuria was inhibited
by pre-treatment with catalase, and by desferrioxamine which suggested that its
toxicity is iron dependent (Yoshioka et al., 1991). Many glomerular diseases have
been associated with high level of reactive oxygen species including puromycin
nephrosis (Ricardo et al., 1975), Heyman nephritis (Shah, 1988) and the Mpv 17 (-/-)
mouse, a model of steroid-resistant FSGS (Binder et al., 1999). Pre-treatment of
these animals with the scavengers of reactive oxygen species has been shown to
prevent foot processes effacement and proteinuria (Ricardo et al., 1975; Shah., 1988;
Grone et al., 1997; Binder et al., 1999).
It has been reported that mechanical stress induces a change in cultured mouse
podocyte morphology and actin skeleton reorganization, like thinning and elongation
of foot processes and reduction in cell body size (Endlich et al., 2001). Mechanical
stress decreases podocytes growth (Petermann et al., 2002).
The understanding of podocyte role in the development of experimental glomerular
disease and proteinuria made them a potential target of treatment of proteinuria in
clinical practice. This was described in Angiotensin converting enzyme (ACE)
inhibitors (Ruggeneti et al., 2000) and angiotensin II (Ang II) receptors blockers
(Nakamura et al., 1999) which have beneficial effects on proteinuria and progression
of chronic renal disease.
40
It has been suggested that podocytes counteract the pressure dependent elastic
distension of glomerular capillaries. Failure to do so in the presence of high
glomerular pressure leads to capillary dilatation, a condition which was reported to
precede the development of segmental glomerulosclerosis (Kriz et al., 1998b). Based
on that ACE inhibitors and Ang II receptors blockers protect podocytes indirectly by
controlling high glomerular pressure and in turn prevent the development of
glomerulosclerosis.
Podocyte injury and nephron loss
There is strong evidence to support the hypothesis that, if podocyte can not be readily
replaced in glomerular disease, as suggested above this may lead eventually to
nephron loss, reduction in renal function and development of chronic renal diseases.
Podocyte injury can lead to glomerular degenerative and inflammatory changes and
development of FSGS and glomerular crescent respectively (Pavenstadt et al., 2003).
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by Kriz's group in different animal models of glomerular diseases including;
glomerular hypertension (Nagata et al., 1992), after long treatment with FGF-2 (Kriz
et al., 1995b) and in Milan normotensive rats (Floege et al., 1997).
The degenerative changes of podocytes in glomerular diseases (figure 1.6) consists
of cell hypertrophy, foot process effacement, cell body attenuation, pseudocyst
formation, cytoplasmic overload with reabsorbtion droplets, and finally detachment
from GBM. Foot process effacement is the result of adaptive changes in cell shape
and hypertrophy of the contractile apparatus which reinforces the supportive role of
podocytes (Shirato et al., 1996), cell body attenuation and pseudocysts are the result
of mechanical overexpansion (Nagata et al., 1992), cell hypertrophy is due to
hyperfiltration (Nagata et al., 1992), accumulation of absorption droplets is because
of increased lysosomal uptake and degradation of filtered proteins (Davies et al.,
1978) and finally podocyte detachment from GBM is due to impaired connection
with it (Cho et al., 1993).
41
Kriz and colleagues (2001) reported that podocyte loss could lead to nephron
degeneration via three steps. The first step is podocyte loss, and because the
remaining podocytes are unable to replicate they compensate for their loss by
hypertrophy to take over the increased load of work. The second step is tuft adhesion
formation, and that when the remaining podocytes fail to cover the places of lost
podocytes the naked GBM will result allowing access to GBM by parietal epithelial
cells of Bowman's capsule. A gap in the parietal epithelium will develop and the
injured glomerular tuft portion will be in direct contact with the interstitium through
it. Such a circumscribed tuft adhesion is the initial lesion in the development of
segmental glomerulosclerosis. The third step is misdirected filtration when the
capillaries in the tuft adhesion deliver their filtrate into the space between the parietal
epithelium and its basement membrane instead of into Bowman' capsule. Interstitial
fibroblast will response to that by making a dense cover of sheetlike processes to
enclose the focus of misdirected filtration, preventing the filtrate from spread to the
surrounding interstitium. This leads to the formation of crescent-shaped
paraglomerular space which by the effect of continuing filtration tends to enlarge by
separating the parietal epithelium from its basement membrane in all directions. As a
result to that the parietal epithelium gap will increase and the adherent sclerotic tuft
will become progressively herniated in the enlarging paraglomerular space.
Hir and co-worker (2001) postulated that the glomerular inflammation starts inside
the GBM and podocytes become involved through the spread of inflammatory
mediators and stimulate a hyperactive response of podocytes. Podocytes develop
large number of retracted fingerlike processes at their apical cell surface. These
processes extend in all direction and may touch the parietal epithelium, pierce
through it between the parietal epithelial cells and fix to the parietal basement
membrane. This leads to the stimulation and proliferation of the parietal epithelial
cells and formation of a cellular crescent.
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Figure 1.6. Podocyte degenerative changes.
Injured podocyte with foot process effacement (Pavenstadt et al., 2003)
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Podocyte injury and loss in urine
A non-invasive technique for the diagnosis of podocyte shedding was described by
Hara and colleagues (1995), who examined the urinary sediment of 59 patients with
different renal diseases and 12 healthy control aged 3-23 years (table 1.1) by indirect
immunofluorescence using a monoclonal antibody to podocalyxin (a glycoprotein
prominently expressed on podocytes). They reported three different structures (casts,
cells and granules) which stained positive for podocalyxin in the urinary sediments.
The number of casts and cells were counted in each partitioned area on a slide
(cytospun urine sediments on the slides were partitioned into 6 areas of
approximately 1X1 cm2 each by PAP pen) and scored as, 0 = none/area,
1 = 1-10/area, 2 = 11-30/area and 3 = >31/area. The amount of granules was scored
as, 0 = none/area, 1 = a few/area, 2 = moderate/area and 3 = numerous/area. Their
results (table 1.1) showed that casts were found in the urinary sediment of 33% of
patients with Lupus nephritis, 50% of patients with minimal change and IgA
nephropathies, 75% of patients with mesangiocapillary glomerulonephritis and 100%
of natients with Alnort svndrome: nost-streotococcal acute ulomerulonenhritis and
A A ' A A U A
Henoch-Schoenlein purpura nephritis. Cells positive for podocalyxin were found in a
few patients with lupus nephritis, IgA nephropathy and Alport syndrome as well as
all patients with post-streptococcal acute glomerulonephritis and Henoch-Schoenlein
purpura nephritis. Granules were found in all patients with membranous
nephropathy, Alport syndrome, post-streptococcal acute glomerulonephritis and
Henoch-Schoenlein purpura nephritis as well as some patients with
mesangiocapillary glomerulonephritis, minimal change, lupus nephritis and IgA
nephropathies. The urinary sediment from control subjects, patients with urological
diseases, patients with non-glomerular haematuria, post-transplantation and renal
failure were negative for podocalyxin. This group concluded that podocytes and their
related structures which are positive for podocalyxin are excreted in the urine in
different types of glomerulonephritis, particularly those with acute onset, and their
amount reflect the degree of podocyte injury in glomerular diseases.
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Cases & Number Casts Cells Granules
0 1 2 3 0 1 2 3 0 1 2 3

















1 2 1 4 3 1
Minimal change
nephropathy (6)
3 3 6 3 2 1
Lupus nephritis (6) 4 2 5 1 4 1 1
IgA nephropathy
(12)
6 2 1 3 10 2 3 7 2




2 3 2 2 1 2 2 1
Henoch-Schoenlein
purpura nephritis (4)
1 3 1 2 1 1 2 1
Table 1.1: Urinary podocalyxin excretion in different renal diseases
(Hara et al., 1995)
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Based on their results from the above study, that urinary podocytes were absent in
normal control, non-glomerular diseases (urological diseases and non-glomerular
haematuria) and glomerular non-inflammatory diseases (minimal change and
membranous nephropathies) and their presence in the urine of glomerular
inflammatory diseases (lupus nephritis, IgA nephropathy, Alport syndrome,
post-streptococcal acute glomerulonephritis and Henoch-Schoenlein purpura
nephritis), the same group was (1998) examined the urine from a group of patients
and control subjects focusing only on the whole urinary podocytes in these different
diseases and not other structures since their number may reflect their injury occurring
in the glomeruli .Also they looked at the difference between acute (within 6 months
after disease onset) and chronic (more than 6 months after disease onset) diseases.
They used a modified scoring system from the above study (0 = none/area, 1 = 1-
3/area, 2 = 4-10/area, 3 = 11-30/area, 4 = >31/area), and reported that normal control,
patients with non-glomerular diseases and patients with glomerular non¬
inflammatory diseases showed no podocytes in their urine. Podocytes were detected
in the urine from patients with glomerular inflammatory diseases. Also, significantly
higher scores of urinary podocytes were found in the acute than chronic disease
(table 1.2).
The role of podocyte injury in the acute phase of glomerular disease became more
obvious when the same group could not detect any urinary podocytes using anti-
podocalyxin antibody from patients with chronic renal failure but could from healthy
controls as well as positive control subjects who were patients with active IgA
nephropathy and normal renal function. They concluded that urinary podocytes may
be used as a marker of disease severity during the acute but not the chronic stage of
renal disease (Ebihara et al., 2000).
Monoclonal anti-podocalyxin antibody was used to stain the urine samples of
patients with diabetic nephropathy in different stages to study the role of podocytes
in this disease as well as the effect of angiotensin converting enzyme inhibitor
trandolapril on podocytes injury (Nakamura et al., 2000b). Urinary podocytes were
absent in healthy controls, diabetic patients with normoalbuminuria and diabetic
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Cases & Number Urinary podocytes
0 1 2 3 4
Normal Normal control (12) 12













Glomerular inflammatory diseases Haemolytic uraemic
syndrome (2)
1 lo












Lupus nephritis (7) 3 1* 3*





Table 1.2: Urinary podocytes in different renal diseases (Hara et al., 1998).
Acute (o) = within 6 months after disease onset.
Chronic (*) = more than 6 months after disease onset.
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patients with chronic renal failure. Podocytes were detected in diabetic patients with
macroalbuminuria and microalbuminuria. Podocytes were significantly higher in
diabetic patients with macroalbuminuria than microalbuminuria which reduced after
2 months treatment with trandolapril in the both groups.
FSGS can be missed on renal biopsy of patients with nephrotic syndrome. Nakamura
and associates (2000c) stained urine samples from patients with nephrotic syndrome
due to minimal change glomerulonephritis and idiopathic FSGS with podocalyxin
antibody to see any difference between them in terms of urinary podocytes. Also
they studied the effect of immunosuppressive therapy on urinary podocytes level.
After 6 months of treatment with prednisolone of minimal change nephropathy
patients, all of them achieved remission and after 12 months of treatment with
prednisolon and cyclophosphamide or mizoribine of idiopathic FSGS patients, half
of them achieved remission. Urinary podocytes were not detected in the healthy
controls and in patients with minimal change glomerulonephritis. Podocytes were
detected in the urine of all patients with idiopathic FSGS before treatment (mean, 4.2
cells/ml) then decreased in the patients who achieved remission (mean, 1.2 cells/ml).
The urinary podocytes did not change in the other patients who did not achieve
remission even after the treatment. They concluded that urinary podocytes can be
used as a diagnostic tool to differentiate between minimal change nephropathy and
FSGS. Podocytes can also mark disease progression in FSGS.
Another study was conducted by Hara and co-workers (2001) to look at podocyte
injury in FSGS. Urine samples of patients with minimal change nephropathy,
membranous nephropathy and FSGS were stained with monoclonal podocalyxin
antibody as above. They reported higher podocyte excretion in focal and segmental
glomerulosclerosis (median, 1.3 cells/ml) in comparison to minimal change
nephropathy (median, 0 cells/ml) and membranous nephropathy (median, 0 cells/ml).
These results supported an important role of podocyte injury in the pathogenesis of
FSGS.
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Urine samples from patients with systemic lupus erythematosus were examined with
the same technique (see above) to look at the role of podocytes (Nakamura et al.,
2000d) in this disease. Two groups of patients were studied, one group with active
disease and another group with stable disease. Podocytes were detectable in the first
group but not in the clinically stable patients. Patients with podocytes in urine were
examined monthly for podocytes and after treatment with methylprednisolone
followed by prednisolon they were absent. They concluded from this study that
urinary podocytes may be used for the assessment of disease severity in lupus
nephritis.
The same group reported later that urinary podocytes can be reduced in renal patients
with proper treatment and argued that could be a reflection of the alteration of
podocytes injury process (table 1.3).
The viability of urinary podocytes has been investigated in experimental renal
diseases. Petermann and colleagues (2003) studied the urinary podocytes from rats
with experimental membranous nephropathy. Urine was collected from these rats,
centrifuged, resuspended in tissue culture media and then seeded on collagen coated
tissue culture plates. The cell number was measured, the cell type was identified by
staining with podocytes specific antibodies and the cell morphology was assessed by
light and electron microscopy. The cells stained positive for podocytes specific
proteins (synaptopodin, nephrin, podocin, WT1 and GLEPP1) when they obtained
from the urine and express podocytes specific proteins at the level of mRNA and
proteins when they grew in tissue culture. Podocyte foot processes were show with
electron microscopy. Podocytes number increased during the first 5 days in tissue
culture but apoptosis increased dramatically to reduce the number of podocytes. A
similar study was conducted by the same group in rats with experimental diabetic
nephropathy and they were able to grow viable podocytes in tissue culture






















mean, 0.4 cells/ml Nakamura et
al., 2000a











mean, 1.3 cells/ml Nakamura et
al., 2000e
















































mean, 0.9 cells/ml Nakamura et
al., 2005
Table 1.3: Effect of treatment on urinary podocytes.
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Aims of the project
The general aim of this project was to study the role of the podocyte in proteinuric
renal disease. Podocytes are highly specialized and terminally differentiated
epithelial cells located on the outer surface of the GBM. Their foot processes
interdigitate around the GBM and form the filtration slits which are the principle
structures for glomerular filtration.
Proteinuria is a manifestation of early podocyte injury even without any changes in
the glomerular structure, and further damage to podocytes is central to the
development of glomerulosclerosis and chronic renal failure.
Mutations of the podocyte proteins genes cause inherited proteinuric diseases
including; Finnish type nephrotic syndrome, congenital nephrotic syndrome,
autosomal recessive FSGS, autosomal dominant FSGS and primary steroid-resistant
FSGS.
Detection of urinary podocytes and/or their fragments with immunofluorescence
(using podocyte protein antibody) in the urine of patients with proteinuric renal
diseases has been reported mostly by one group to reflect disease activity.
The specific aims of this project were:
1. To test the hypothesis that it would be prognostically useful to be able to
identify podocytes in urine of patients with proteinuric renal disease, and that
a reverse transcriptase polymerase chain reaction method would be an
efficient and clinically applicable way to do this (chapter 3 and chapter 4).
2. To create an animal model in which a graded podocyte injury could be
induced, and examined alone or in combination with other pathology. This
would be useful to test the hypothesis that treatment that protects the







Oligonucleotide primers were obtained from TANG Ltd except random hexamer
pd(N)6 from Promega and M13For and M13Rev primers from haematology
department of Edinburgh Royal Infirmary
cDNA oligonucleotide primers
• Nephrin cDNA primers
1. HuNephlFor
HuNephlRev
Band size is 310bp
2. HuNeph2For
HuNeph2Rev
Band size is 377bp
• Podocalyxin cDNA Primers
1. HuPodolFor
HuPodolRev
Band size is 290bp
2. HuPodo2For
HuPodo2Rev
Band size is 217bp
• P-actin cDNA Primers
B-actinFor 5 -CCA CCA ACT GGG ACG ACA TG-3V
B-actinRev 5 -GTC TCA AAC ATG ATC TGG GTC ATC-3V
Band size is 150bp
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5-GAG AGG ACC ACC TCA GGC AG-3V
5V-GCT CTC GGT TCA CTG TCT CC-3V
5-GAA TTG CTG AAG GAT GGG AA-3V
5-GGT GCT TCC CAC TTT GTT GT-3V
5"-GAC AGC AAA TAG GCC TCT GC-3V
5s-ATA GGT GTC CTG GTG GCA AG-3^
5-TGG GAG TGA TTC CCT GAG AC-3V
5-GTC TGA GCT TTT GGC CTT TG-3V
DNA oligonucleotide primers
• pMS7 sequencing primers
M13For and M13Rev
• Murine nephrin gene fragment PCR primers
MONPHSF1 5V-GCC GCC GGG AGG TGA GAG GTT TGT AG-3^
MONPHSNotF2 5-TCC TGG AGA AGC GGC CGC CGG GAG-3V
MONPHSBamREV 5-CTG TGG GAT CCT TAG CTC CCA TCA C-3N
MonephBamRev2 5-AGC TCG GAT CCA CCA GCA GCT-3
Band size is 1315bp
• pCR4BN sequencing primers
M13For and M13Rev
• pIN sequencing primers (figure 2.1)
M13Rev and M13 Rev
5-ATG GCC CAG GGA TTC AGG TGC-3V
5-GCT TGG ACC CAG TGT GAA CTC-T
5 -GCT GGT GAT GGG AGC TAA GGA-3V
5V-ATC ATG AGG GTC CAT GGT GAT-3"
5V-GGT TAT TGT GCT GCT TCA TCA-3V
5-GAT AGG CAG CCT GCA CCT GAG-3V
5-TCC AAA CCG GGC CCC TCT GCT-3V










Mice genotyping primers (figure 2.2)
1. pINPCR-Forl
pINPCR-Revl
Band size is 243bp
2. pINPCR-For2
pINPCR-Rev2
Band size is 228bp
5-GGA AGA GAG AAG GGC GAG TT-3V
5 -GGG TCC ATG GTG ATA CAA GG-3V
(nephrin gene/intron genotyping)
5-GGT GGT GCT GAA GCT CTT TC-3V




Figure 2.1: Map of pIN sequencing primers
1 = M13Rev 2 = MonephrinMidFor
3 = monephrinMidRev 4 = monephrin3pFor
5 = B-intronRev 6 = EGF-For2
7 = EGF-For 8 = EGF-Rev











Molecular biology enzymes were obtained from Promega, total RNA isolation mini
kit was obtained from Agilent and DNA was prepared by QLAGEN kit. The plasmid
pMS7 was a gift from Dr Saito.
The other materials are described in the methods.
Patients
Total RNA was extracted from urine samples (20 ml each) of 70 proteinuric (urine
protein >+++) renal patients at the renal outpatient department of Edinburgh Royal
Infirmary. Immunofluorescence studies were conducted on urine samples of 100
patients with similar criteria.
Although individual samples were anonymised, they were known to include samples
from patients with diagnosis of minimal change disease, FSGS, membranous
nephropathy, IgA nephropathy and lupus nephritis (muitipie examples in each case)
Ethical permission and approval
Ethical Committee approval was obtained for the human studies in this project and




Total RNA extraction by TRIzol
Urine samples were collected and kept at room temperature until processed (within
3-4 hours). The samples were centrifuged at 2500 rpm for 5 minutes at 4°C and the
pellets were resuspended in 500 ul of urine, divided into two Eppendorff tubes and
homogenised in 800 ul of TRIzol (phenol and guanidine thiocyanate) from
Invitrogen (Chomczynski and Sacchi, 1987). After addition of 100 ul of chloroform,
samples were vortexed, incubated on ice for 5 minutes and centrifuged at 14,000 rpm
for 5 minutes. The aqueous and organic layers were separated. RNA was precipitated
from the aqueous layer by adding an equal volume (300 ul) of isopropanol, followed
by incubation at room temperature for 10 minutes, adding at this stagelO ul of
glycogen (Invitrogen), followed by centrifugation at 14,000 rpm for 5 minutes. The
pellets were washed with 500 ul of ethanol 75% and dissolved finally in 15 ul of
nuclease-free water.
DNasel treatment and cDNA synthesis
DNasel treatment of the extracted total RNA and cDNA synthesis for use in the
polymerase chain reaction were carried out using two methods.
In the first method (Konnai et al., 2003) this was done in two steps.
Firstly, 1 ul DNasel (1 u/ul) was added to the total RNA (50 ul) and incubated at
room temperature for 15 minutes. 1 ul of 25mM EDTA was added then they were
incubated at 65°C for 10 minutes to inactivate the DNasel, which could otherwise
destroy the cDNA later. This was followed by ethanol precipitation to remove the
EDTA (which may inactivate the reverse transcriptase during cDNA synthesis), by
adding 1/10 volume of 5M NaCl (5 ul) and 3 volumes of ethanol 100% (150 ul). This
reaction was incubated at -20°C for 2 hours, and then was spun at 14,000 rpm for 5
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minutes. The pellet was washed with 250 ul of ethanol 75%, and finally dissolved in
30 ul of nuclease-free water.
Secondly, cDNA synthesis was done in three different reactions as below:
Reagent DNaseI+/RT+ DNaseI-/RT+ DNaseI-/RT-
AMV RT buffer (5X) 5 ul 5 ul 5 ul
(see below for composition)
NTPs (1:10) 1 ul lul lul
Rnase inhibitor 0.5 ul 0.5 ul 0.5 ul
AMV RT (5 units) 0.5 ul 0.5 ul -
Nuclease-free water 10 ul 10 ul 10.5 ul
17 ul 17 ul 17 ul
3 ul of random hexamer [pd(N)6] and 5 ul of total RNA were heated at 70°C for 10
minutes, then cooled at room temperature for 10 minutes before the 17 ul reaction
mixture was added (25 ul reaction). These then were incubated at 42°C for one hour.
The second method (Huang et al., 1996), allows DNasel to work in the AMV RT
buffer (5X - 250mM Tris-HCl, 250mM KC1, 50mM MgC12, 2.5mM spermidine and
50mM DTT). DNasel was inactivated by heat alone to minimise RNA loss during its
ethanol precipitation and other manoeuvres. This method all takes place in a single
tube.
The method as below:
Reagent DNaseI+/RT+ DNaseI-/RT+ DNaseI-/RT-
RNA 5 ul 5 ul 5 ul
RT buffer (5X) 5 ul 5 ul 5 ul
NTPs lul lul lul
Rnase inhibitor 0.5 ul 0.5 ul 0.5 ul
Nuclease-free water 9 ul 10 ul 10.5 ul
Rnase-free DNasel lul _ _
21.5 ul 21.5 ul 21.5 ul
59
The reagents were incubated at 37°C for 30 minutes, then at 75°C for 10 minutes.
3 ul of pd(N)6 was added and continued at 75°C for further 5 minutes. The reagents
were left to cool at room temperature for 10 minutes before 0.5 ul of AMV-RT
(5 units) was added to the (DNaseI+/RT+) and (DNaseI-/RT+) reactions. All were
incubated at 42°C for one hour.
cDNA Polymerase chain reaction
This was performed by using Ready to Go PCR beads (Amersham Pharmacia
Biotech Inc). These premixed 0.2 ml thin-walled tubes contain buffers, dNTPs, Taq
DNA polymerase enzyme (2.5 units), stabilizers and Bovine Serum Albumin (BSA).
When dissolved in a final volume of 25 ul PCR reaction (20.5 ul of nuclease-free
water, 1 ul of 25mM MgC12, 0.75 ul of forward primer, 0.75 ul of reverse primer and
2 ul of cDNA which was added after the hot start as explained below) the beads at
this stage contains 200uM in lOmM Tris-HCl (pH 9 at room temperature) of each
dNTPs, 50mM KC1 and 2.75mM of MgC12 (1 ul of 25mM MgC12 was added to
beads content of 1.5mM of MgC12). This reaction was subjected to hot start in the
PCR machine at 75°C for 10 minutes followed by addition of 2 ul of the cDNA. The
program was; 95°C for 1 minute (denaturation); 65°C for 1 minute (annealing); 72°C
for IV2 minute (elongation) and run for 30 cycles. The final elongation temperature
was 72°C for 10 minutes.
DNA extraction from cultured human B cells
10 ml of cultured human B cells (DR2Lum) were provided kindly by Dr Juan Zou.
The concentration of them was one million cell/ml. They were divided in two tubes
(5ml each) and centrifuged at 12,000 rpm for 5 minutes at 4°C. The supernatants
were discarded and the pellets were resuspended in 200 ul of phosphate buffered
saline (PBS). The mixtures were incubated at 70°C for 10 minutes after addition of
20 ul of proteinase K. 200 ul of ethanol (100%) was added and mixed thoroughly
before were transferred into DNeasy spin columns (Qiagen) and placed in 2 ml
collection tubes (provided with the buffers), then centrifuged at 8000 rpm for one
minute at room temperature (the principle of this method is that buffering conditions
are adjusted to provide optimal DNA-binding conditions when the lysate loaded on
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the DNeasy spin columns and during a brief centrifugation DNA will bind
selectively to the DNeasy membrane and the contaminants pass through. DNA eluted
after two washing steps). The flow-through and collection tubes were discarded and
the DNeasy spin columns were placed in new collection tubes. 500 ul of buffer AW1
was added and centrifuged at 8000 rpm for one minute at room temperature. The
flow-through and collection tubes were discarded and the DNeasy spin columns were
placed in new collection tubes. 500 ul of buffer AW2 was added and centrifuged at
14,000 rpm for 3 minutes at room temperature to dry the DNeasy membranes. The
flow-through and collection tubes were discarded and The DNeasy spin columns
were placed in eppendorff tubes. 200 ul of buffer AE was added (to elute DNA),
incubated at room temperature and spun at 8000 rpm. The extracted DNA was
checked by loading 2 ul of each sample on agarose gel 1% and visualized under
ultraviolet transilluminator by ethidium bromide (figure 2.3). The concentration of
the DNA was measured after combination of both samples (400 ul) and found to
be100 ng/ul which is diluted and because of that ethanol precipitation was done.
Ethanol precipitation was by adding 1/10 of 3M Na acetate (40 ul) and 2 volumes of
100% ethanol (800 ul), and then incubated at -20°C for 30 minutes. This mixture was
spun at 14,000 rpm at room temperature for 10 minutes and the supernatant was
discarded. The pellet was washed by 1 ml of ethanol 70% and spun for one minute at
room temperature. The supernatant was discarded; the pellet was air dried and
dissolved in 40 ul of lOmM Tris CI (pH 8.5). DNA concentration was 500 ng/ul.
Total RNA extraction by Agilent total RNA isolation mini kit (phenol-free
method)
Urine samples were collected as described above and centrifuged at 2500 rpm for 5
minutes at 4°C and the pellets were resuspended in 500 ul of lysis solution (contains
guanidine isothiocyanate)/p-mercaptoethanol mixture; then transferred into mini
prefiltration column and centrifuged at 14,000 for 3 minutes at room temperature
(most of DNA and other contaminants are removed at this stage). 600 ul of ethanol
(70%) was added to the filtrate and mixed till it become homogenous. 700 ul of
ethanol/lysis mixture was transferred into mini isolation column and centrifuged at
14,000 rpm for 30 seconds at room temperature(RNA loaded from the mixture on the
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1 2 Hae III
Figure 2.3. Extracted human genomic DNA
No.l and 2 is human genomic DNA which was extracted from cultured human B
cells.
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column at this step);the flow-through was discarded and RNA loaded column was
transferred into collection tube. 500 ul of wash solution was added and centrifuged at
14,000 for 30 seconds at room temperature; flow-through was discarded and the
column replaced in another collection tube (the washing step was done twice). The
mini isolation column was spun dry at 14,000 rpm for 2 minutes at room temperature
and RNA was eluted by adding 20 ul of nuclease-free water; incubated at room
temperature for 1 minute and spun at 14,000 for 1 minute at room temperature.
Agarose gel electrophoresis
Agarose (CLP) was weighed in a small flask and 50 ml of buffer TBE (lx) was
added. The agarose was melted by heat in a microwave at 60°C for 60 seconds. Once
the agarose melted 5 ul of ethidium bromide (attach to cDNA to be visualised by
ultraviolet transilluminator) was added; and then poured in gel electrophoresis
apparatus. The agarose was left to polymerize by cooling at room temperature for 30
minutes. Loading buffer was used to load cDNA/DNA and Hae III (DNA marker)
after removing gel tank edges and tooth barrier as well as covering the gel with 50 ml
of buffer TBE (lx). The electrophoresis machine was sat at lOOv; 25w; 75mA and
run for 45 minutes. The gel was visualised by ultraviolet transilluminator to look for
the appropriate band size and finally photographed.
cDNA oligonucleotide primers
The national centre for Biotechnology Information (NCBI) Entrez Gene database
was used to search for human nephrin and podocalyxin cDNA sequences. The
primer3 program (http://frodo.wi.mit.edu/cig-bin/primer3-www.cgi) was used to
design two pairs of primers for nephrin and podocalyxin cDNA (band size range
200-400 bp). P-actin primers (common for mouse and human) were provided kindly
by Dr Julia Marley. When the primers were received aliquots of 1 ug/ul in water
were made. 1/10 dilution from these aliquots was used as the working dilution for
PCR. The conditions of these PCRs were optimized using a human kidney cDNA
(control cDNA) which was provided kindly by Professor Neil Turner, and then these
primers were used to do cDNA PCR for nephrin and podocalyxin.
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Making and transformation of competent E.coli (DH5) with plasmid DNA
The E.coli was grown on agar plate (without added antibiotic) by overnight
incubation at 37°C. In the following day 50 ml of SOB medium with added
magnesium sulphate in sterilized (with boiling water) grooved flask was inoculated
with 5-10 colonies from E.coli plate. The flask with its contents was incubated in a
shaker at 225 rpm for 3-5 hours at 37°C till the optical density of E.coli was 0.3-0.4
at 550 nm. After that the contents was transferred to chilled 50 ml falcon tube,
centrifuged at 2000-4000 rpm at 4°C for 10 minutes, then the supernatant was
discarded and the bacterial pellet was resuspended in 10-15 ml of chilled
transforming buffer. The mixture was incubated on ice for 10-15 minutes then
centrifuged as above and the bacterial pellet was resuspended in 2-5 ml of chilled
transforming buffer. 140 ul of DD solution was added into the centre of the mixture
then the whole tube contents were swirled immediately. The mixture was incubated
on ice for further 10 minutes and then 140 ul of DD solution was added and
incubated for 20 minutes on ice. 50 ul of E.coli in transforming buffer and DD
solution mixture and few microlitres of plasmid DNA (amount and dilution depend
on DNA concentration of each plasmid) was mixed together in a microcentifuge tube
and incubated on ice for 30 minutes. E.coli in the mixture was subjected to heat
shock by incubation in a water bath at 42°C for 90 seconds followed by incubation
on ice for 2 minutes. 200 ul of SOC medium (pre-warmed at room temperature) was
added and incubated in a shaker at 225 rpm for 60 minutes at 37°C. The contents
then were spread on agar plate with added ampicillin, inverted and incubated
overnight at 37°C and the following day stored at 4°C for further experiments.
Transformation of competent E.coli with plasmid DNA
The plasmid DNA was added to a vial of competent E.coli (One Shot, Invitrogen)
and incubated on ice for 5 minutes. E.coli was subjected to heat shock by incubation
in a water bath at 42°C for 30 second followed by incubation on ice for 2 minutes.
During ice incubation 250 ul of SOC medium (pre-warmed at room temperature) was
added. The mixture was incubated horizontally in a shaker at 225 rpm for 60 minutes
at 37°C. The contents then were spread on agar plate with added ampicillin, inverted
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and incubated overnight at 37°C and the following day stored at 4°C for further
experiments.
Making of agar plates
Bacto-agar was added to SOB medium to make 1.5% (1.5 g/lOOml) agar plates and
autoclaved. Once the temperature of the mixture reached approximately 50-55°C
ampicillin was added (1 ul of 50 mg/lOOml of ampicillin per 1 ml of the mixture). 30
ml was poured per each 90 mm Petri dish and stored at 4°C till used.
Minipreparation of plasmid DNA
The minipreparation technique was used for the production of small quantities of
plasmid DNA from transformed E.coli for restriction enzyme analysis. 15 ml tubes
with 2 ml of LB medium and 2 ul of 50 mg/ml ampicillin was inoculated with a
single colony of transformed E.coli (to avoid contamination) and incubated in a
shaker at 225 rpm overnight at 31°C. The following day 1.5 ml was processed for
DNA extraction and 0.5 ml was saved at 4°C for plasmid DNA midipreparation. The
1.5 ml volume was transferred to a microcentifuge tube and centrifuged at 14,000
rpm for 3 minutes at room temperature and the supernatant was aspirated and
discarded. The bacterial pellet was resuspended in 100 ul of GTE by vigorous
vortexing, then 200 ul of 0.2 M NaOH/0.1% SDS solution was added and mixed by
inversion 4-6 times. To this mixture 150 ul of chilled 5M/3M potassium acetate was
added, mixed be gentle vortex and incubated on ice for 15 minutes. The contents
were centrifuged at 14,000 rpm for 5 minutes at room temperature and the
supernatant was transferred to a new microcentifuge tube and 200 ul of phenol was
added. This was followed by vortex and centrifugation at 14,000 rpm for 2 minutes
at room temperature. The top layer (approximately 300 ul) of the supernatant was
transferred to third microcentrifuge tube. DNA was precipitated by 100 ul of 100%
isopropanol, then mixed together by vortex and centrifuged at 14,000 rpm for 5
minutes at room temperature. The supernatant was discarded and DNA pellet was
washed with 1 ml of 70% ethanol. The supernatant was discarded and DNA pellet
was left to air dry for 10-15 minutes at room temperature and finally it was dissolved
in 30-40 ul of TE buffer, 5-10 ul ofwhich were used for restriction enzyme analysis.
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Midipreparation of plasmid DNA
The midipreparation technique was used for the production of medium quantities and
clean qualities of plasmid DNA from transformed E.coli for plasmid DNA
sequencing because RNA is destroyed by RNase in this technique. This was done
using plasmid DNA midiprep kit from Qiagen. A grooved sterile (with boiling water)
flask with 50 ml of LB medium and 50 ul of 50 mg/ml ampicillin was inoculated
with 100 ul of the saved plasmid DNA minipreparation after its restriction enzyme
analysis and incubated in a shaker at 225 rpm overnight at 37°C. The following day
the bacterial suspension was transferred to an Oakridge tube and centrifuged at 6000
rpm for 15 minutes at 4°C. The supernatant was discarded and the bacterial pellet
was resuspended in 4 ml buffer PI with added RNase and mixed by vortex. 4 ml of
buffer P2 was added and mixed by gentle inversion for 4-6 times, then incubated at
room temperature for 5 minutes. 5 ml of chilled buffer P3 was added, mixed gently
immediately by inversion for 4-6 times and then incubated on ice for 15 minutes. The
mixture was centrifuged at 13,000 rpm for 30 minutes at 4°C and the supernatant
was transferred to another Oakridge tube. The supernatant was recentrifuged at
13,000 rpm for 15 minutes at 4°C and during this stage a Qiagen-tip 100 was
equilibrated by 4 ml of buffer QBT and the column was allowed to empty by gravity.
The supernatant was applied to Qiagen-tip 100 and it was allowed to enter the resin
by gravity flow. This tip was washed twice by 10 ml of buffer QC which was
allowed to flow by gravity. Plasmid DNA was eluted from the tip with 5 ml of buffer
QF in a third Oakridge tube and precipitated by 3.5 ml of room temperature
isopropanol. The mixture was mixed and centrifuged at 11,500 rpm for 30 minutes at
4°C and the supernatant was discarded. 2 ml of 70% ethanol was added, then divided
into two microcentifuge tubes, centrifuged at 14,000 rpm at room temperature for 10
minutes and the supernatant was discarded. Plasmid DNA pellets were air dried at
room temperature and finally dissolved in 10-20 ul of TE buffer and the two samples
were combined. The optical density of DNA was measured by ultraviolet
spectrophotometer. This plasmid DNA was tested with restriction enzyme analysis
and used for plasmid DNA sequencing.
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Maxipreparation of plasmid DNA
The maxipreparation technique was used for the production of large quantities and
clean qualities of pIN plasmid DNA (podocyte construct) from transformed E.coli to
use for mice microinjection. This was done using plasmid DNA maxiprep kit from
Qiagen. A grooved sterile (with boiling water) flask with 50 ml of LB medium and
50 ul of 50 mg/ml ampicillin was inoculated with 100 ul of the saved plasmid DNA
minipreparation after its restriction enzyme analysis and sequencing of its
midipreparation DNA incubated in a shaker at 225 rpm overnight at 37°C. This was
used to inoculate 500 ml of LB with 500 ul of 50 mg/ml ampicillin and incubated as
above. The following day the bacterial suspension was transferred to a 500 ml
centrifugation bottle and centrifuged at 5100 rpm for 25 minutes at 4°C. The
supernatant was discarded and the bacterial pellet was resuspended in 10 ml of buffer
PI with added RNase and mixed by vortex and transferred to Oakridge tube. 10 ml
of buffer P2 was added and mixed by gentle inversion for 4-6 times, then incubated
at room temperature for 5 minutes. 10 ml of chilled buffer P3 was added, mixed
gently immediately by inversion for 4-6 times and then incubated on ice for 20
minutes. The mixture was centrifuged at 13,000 rpm for 30 minutes at 4°C and the
supernatant was transferred to another Oakridge tube. The supernatant was
recentrifuged at 13,000 rpm for 15 minutes at 4°C and during this stage a Qiagen-tip
500 was equilibrated by 10 ml of buffer QBT and the column was allowed to empty
by gravity. The supernatant was applied to Qiagen-tip 500 and it was allowed to
enter the resin by gravity flow. This tip was washed twice by 30 ml of buffer QC
which was allowed to flow by gravity. Plasmid DNA was eluted from the tip with 15
ml of buffer QF in a third Oakridge tube and precipitated by 10.5 ml of room
temperature isopropanol. The mixture was mixed and centrifuged at 11,500 rpm for
30 minutes at 4°C and the supernatant was discarded. 5 ml of 70% ethanol was
added, then divided into 4 microcentifuge tubes, centrifuged at 14,000 rpm at room
temperature for 10 minutes and the supematants were discarded. Plasmid DNA
pellets were air dried at room temperature and finally dissolved in 20-25 ul of TE
buffer and the 4 samples were combined. The optical density of DNA was measured
by ultraviolet spectrophotometer. This plasmid DNA was tested with restriction
enzyme analysis and used for plasmid pIN DNA microinjection.
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Restriction enzyme analysis of plasmid DNA preparation
This was done for the midipreparation of the plasmid pMS7, minipreparation and
midipreparation of the plasmid pCR4BN as well as minipreparation, midipreparation
and maxipreparation of the plasmid pIN DNA, restriction enzyme and its buffer,
BSA and nuclease free water were incubated at 37°C for one hour.
Sequencing of plasmid DNA midipreparation
This was done for the midipreparation DNA of the plasmids pMS7, pCR4BN and
pIN at haematology department of Edinburgh Royal Infirmary to prove the right
sequences. 500 ng of DNA and sequencing primers (100 pmol/ul) were sent and the
results were received as an electronic version. DNA strider 1.2 was used to read the
results which were checked by Entrez Gene database of the National Centre for
Biotechnology Information (NCBI).
DNA oligonucleotide primers
Murine nephrin gene fragment (podocyte promoter) PCR primers were similar to the
primers used by Moeller and colleagues (2002) with added NotI and BamHI
restriction sites. They reported that 1.25 kb nephrin gene fragment has lead to
specific podocyte expression of betaglactosidase gene and not in any of the other
tested tissue. NotI and BamHI restriction sites are the subcloning sites of this
fragment into pMS7 to produce pIN podocyte construct. The primer3 program
(http://frodo.wi.mit.edu/cig-bin/primer3-www.cgi) was used to design two pairs of
primers for mice genotyping PCRs. When the primers were received aliquots of
lug/ul in water were made and 1/10 dilution from these aliquots was used as the
working dilution for PCR. Sequencing primers of around 21 bp were designed and
their working dilution was 100 pmol/ul.
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Taq DNA polymerase PCR of murine nephrin gene fragment (podocyte
promoter)
This was done first to optimize the conditions of the nephrin gene fragment PCR and
it was consists of two Taq polymerase PCRs. In the first PCR MONPHSF1 primer,
MONPHSBamREV primer and wild type mouse DNA were used. In the second PCR
MONPHSNotF2 primer, MONPHSBamREV primer and first PCR product as a
template to introduce NotI restriction site were used. This was performed by using
Ready to Go PCR beads (Amersham Pharmacia Biotech Inc). These are premixed
0.2 ml thin-walled tubes containing buffers, dNTPs, Taq DNA polymerase enzyme
(2.5 units), stabilizers and Bovine Serum Albumin (BSA). When dissolved in a final
volume of 25ul PCR reaction (20.5ul of nuclease-free water, lul of 25mM MgC12,
0.75ul of forward primer, 0.75ul of reverse primer and 2ul of DNA which was added
after the hot start as explained below) the beads at this stage contains 200uM in
lOmM Tris-HCl (pH 9 at room temperature) of each dNTPs, 50mM KC1 and
2.75mM of MgC12 (lul of 25mM MgC12 was added to beads content of 1.5mM of
MgC12). This reaction was subjected to hot start in the PCR machine at 75°C for 10
minutes followed by addition of 2ul of the DNA. The program was; 95°C for 1
minute (denaturation); 60°C for 1 minute (annealing); 72°C for lVi minute
(elongation) and run for 30 cycles. The final elongation temperature was 72°C for 10
minutes.
Proofreading DNA polymerase PCR of murine nephrin gene fragment
(podocyte promoter)
This PCR was performed using Vent DNA polymerase (New England BioLabs)
because of its lower error rate and to produce blunt ended PCR product. 50 ul
reaction was consisted of 2 ul ofMONPHSNotF2 primer, 2 ul ofMONPHSBamREV
primer, 1 ul of 100 mM MgS04, 4.5 of thermopol buffer (10X), 3 ul of dNTPs, 30.5
ul of nuclease-free water and 2 ul (1:4 dilution) of first Taq DNA polymerase PCR
product. This reaction was subjected to hot start in the PCR machine at 75°C for 10
minutes followed by addition of 5ul of Vent DNA polymerase dilution (1.1 ul of
thermopol buffer, 7.4 ul of nuclease-free water and 1.5 ul; 3 units of Vent DNA
polymerase). The program was; 95°C for 1 minute (denaturation); 60°C for 1 minute
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(annealing); 72°C for IV2 minute (elongation) and run for 30 cycles. The final
elongation temperature was 72°C for 10 minutes. This PCR was repeated as
described above using MONPHSNotF2 primer, MonephBamRev2 and the product of
Vent polymerase PCR as a template (see discussion for details).
Purification of PCR product
This was performed using Qiagen kit (desalting and concentrating DNA from
solutions protocol). The product was transferred from the PCR tube to a
microcentrifuge tube and 3 volumes of buffer QX1 were added to one volume of
PCR product. Qiaex II was resuspended by vortex for 30 seconds and 15-20 ul of it
was added and the mixture then incubated at room temperature for 10 minutes
(vortexed every 2 minutes). The mixture then was centrifuged at 14,000 rpm for 30
seconds at room temperature and the supernatant was removed. The pellet was
washed twice with 500 ul of buffer PE, and then air-dried for 15 minutes until its
colour was changed to white colour. DNA was eluted with 20 ul of lOmM Tris. CI
(Y)H 8.5V centrifuped at 14.000 mm for 30 seconds at room temoerature and the
Vi /' O ' x x
supernatant was transferred to a new microcentrifuge tube because it contains the
pure DNA. 1 ul of the pure DNA was loaded on agarose gel to prove its presence
after the purification.
Subcloning of the nephrin gene fragment into pCR®4Blunt-Topo and
production of pCR4BN
1 ul of nephrin gene fragment (PCR product), 1 ul of pCR4 Blunt-Topo (Invitrogen)
and 1 ul of its salt solution were added to 3 ul of nuclease-free water and incubated at
room temperature for 10 minutes
Gel purification ofDNA
DNA was visualised by ethidium bromide staining on an ultraviolet transilluminator
and the wanted band was excised from agarose gel. DNA was purified from agarose
gel using Qiagen kit (DNA extraction from agarose gels protocol). 1 ml of buffer QX
1 and 10 ul of Qiaex II (resuspended by vortex) were added to the excised gel
fragment which contains the DNA and incubated at 50°C for 10 minutes (vortexed
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every 2 minutes during this incubation). The mixture was centrifuged for 14,000 rpm
for 30 seconds at room temperature and the supernatant was discarded. The pellet
was resuspended in 500 ul of buffer QX 1, centrifuged as above and the supernatant
was discarded. The last step was repeated twice with buffer PE to wash the DNA
pellet which was left at room temperature for 5-10 minutes to air dry. 20 ul of lOmM
Tris. CI (pH 8.5) was added, vortexed, incubated at room temperature for further 5
minutes and then centrifuged at 14,000 rpm for 30 seconds at room temperature. The
supernatant was transferred to a new microcentrifuge tube because it contains the
pure DNA. 1 ul of the pure DNA was loaded on agarose gel to prove its presence
after the purification.
Subcloning of the nephrin gene fragment from pCR4BN into pMS7 and
production of pIN (podocyte construct)
The plasmids pMS7 (vector) and pCR4BN (contains the insert which is the nephrin
gene fragment) were digested with NotI and BamHI restriction enzyme. The plasmid
pMS7 was then dephosphorylated by calf intestinal alkaline phosphatase (promega)
to prevent it from relegation. This enzyme was inactivated by incubation at 70°C for
15 minutes. The restriction digest reactions were loaded on 1% TBE agarose gel and
the appropriate vector and insert band were excised and purified as described above.
The purified vector and insert were ligated with T4 DNA ligase and produced pIN
(podocyte construct). E.coli was transformed with the plasmid pIN and
minipreparation, midipreparation and maxipreparation of its DNA was performed.
Microinjection of murine fertilized ova with the plasmid pIN (podocyte
construct)
In the first trial of murine fertilized ova microinjection, the conditions of NotI and
Xhol enzyme restriction analysis and its photograph, pIN sequencing, pIN map and
50 ul (1 ug/ul) of pIN maxipreparation DNA were sent to the Human Genetic Unit at
Western General Hospital in Edinburgh. In the second trial ofmicroinjection, 3 ug of
pIN maxipreparation DNA was digested with NotI and Xhol restriction enzymes, gel
purified, ethanol precipitated and sent to Rederivation Unit at Edinburgh Royal
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Infirmary with a photograph of the restriction enzyme analysis and a photograph of
the purified liner pIN construct as well as pIN map.
DNA extraction from the potentially transgenic mice ear punches
Sixty nine ear punches of 3 weeks age of mice were sent to us for DNA extraction
and PCR genotyping. DNA was extracted using DNeasy purification kit from
Qiagen. 180 ul of buffer ATL and 20 ul of proteinase K were added to the ear
punches in microcentrifuge tubes, vortexed and incubated at 55°C overnight. The
next day 400 ul of buffer AL (with added ethanol) was added and then vortexed. The
mixtures were transferred to DNeasy mini spin columns placed in 2 ml new
collection tubes and centrifuged at 8000 rpm for 1 minute at room temperature and
the flow through were discarded with their collection tubes. DNeasy mini spin
columns were placed in another 2 ml new collection tubes, 500 ul of buffer AW1
was added and centrifuged at 8000 rpm for 1 minute at room temperature and the
flow through were discarded with their collection tubes. DNeasy mini spin columns
were placed in another 2 ml new collection tubes, 500 ul of buffer AW2 was added
and centrifuged at 14,000 rpm for 3 minute at room temperature to dry the DNeasy
membranes and the flow through were discarded with their collection tubes. DNeasy
mini spin columns were placed in microcentrifuge tubes, 100 ul of buffer AE was
added and incubated at room temperature for 1 minute and centrifuged at 8000 rpm
for 1 minute at room temperature and the eluted DNA was used for genotyping
PCRs.
Southern blotting hybridization of the potentially transgenic mice DNA
Both genotyping PCRs were done on the potentially transgenic mice DNA and were
run on 2% TBE agarose gel. These gels were visualised by ethidium bromide on
ultraviolet transilluminator and photographed were taken with ruler. The DNA was
denatured into ssDNA by soaking the gels into denaturation buffer (1.5M NaCl and
0.5M NaOH) for 30 minutes at room temperature (ssDNA will work as a
complementary strand for the radiolabelled probe) after cutting one edge of the gels
as a marker. The gels then were placed upside down into appropriate amount of
denaturation buffer (works as a transfer buffer) and covered with multiple layers in
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the order; nylon membrane (MEN), two layers of filtering papers (Hybond blotting
paper from Amersham Pharmacia Biotech), two layers of roller tissue and
appropriate weight to press the layers (to transfer the ssDNA from gels to nylon
membrane). This was incubated for 12-24 hours. The nylon membranes then were
peeled off the gels, placed on its back side, marked with blue ballpoint pen for the
cut edges, name, date and wells. These membranes were washed by appropriate
amount of washing buffer; 2X SSC (1/10 of 20X SSC: 0.3M Na acetate and 3M
NaCl) and rotated for 15 minutes. The membranes then were air-dried at room
temperature for 30 minutes. The ssDNA was fixed on the nylon membranes by
sandwiching them between two filtering papers and incubated at 80°C for 30
minutes. The blotted nylon membranes were hybridized at Human Genetic Unit at
Western General Hospital with radiolabeled probes. These probes were the purified
products from PCR amplification of pIN with genotyping primers, which were
radiolabeled with 32p. These PCRs were used as a positive control of the potentially
transgenic mice DNA southern blotting hybridization.
Immunofluorescence methods
Indirect surface staining of cultured human B cells
Two volumes of cultured human B cells (1X106 cells in 200 ul of media) were
provided kindly by Dr Lorna Henderson. These two volumes were placed in two
wells of 96 wells plate and one sample was used for immunofluorescence staining
and the other sample was used as a negative control (no primary antibody was used).
5 ul of the primary antibody (HLA DR7 IgM-Biotinylated Monoclonal Antibody
from One Lambda Inc) was added to the positive sample and both samples were
incubated on ice for 30 minutes. Then they were centrifuged at 1000 rpm for 4
minutes at 4°C and the supernatant was discarded. The cellular pellets were washed
by addition of 200 ul of FACS buffer (0.2% NaN3 and 1% FBS in PBS) with BSA;
which blocks the non-specific binding sites of the secondary antibody, centrifuged as
above and the supernatant was discarded. This washing step was repeated and the
pellets were resuspended in 200 ul of FACS buffer. 5 ul of the secondary antibody
(Streptavidin, R-phycoerythrin conjugate from sigma) was added and incubated on
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ice for 30 minutes. Then they were centrifuged at 1000 rpm for 4 minutes at 4°C and
the supernatant was discarded. To wash the cellular pellets 200 ul of FACS buffer
was added centrifuged as above and the supernatant was discarded. The washing step
was done twice. Finally the pellets were resuspended in FACS buffer, wrapped in
foil, examined with light and immunofluorescence microscopy (a drop of the
suspension was placed on a glass slide and covered with coverslip) with different
magnification and photographed with a digital camera.
Cytospin of cultured human B cells and staining with Haematoxylin and Eosin
Cultured human B cells were provided by Dr Juan Zou. They were spun at 1000 rpm
for 4 minutes at 4°C and resuspended in 1 ml of PBS (contains 1X105 cells which is
the optimal number for good cytospin results in 20 ul of PBS). The cytospin machine
(Cytospin4-Thermo Shandon) was sat at 300 rpm for 3 minutes. Poly-L-lysin coated
glass slides (sigma-aldrich) were marked and dated by pencil then placed in the
metallic device of cytospin machine. The slides were covered with filter papers
which have a hole on each side. Samples containers were placed on the filter papers.
These containers have two opening; the upper opening where the samples loaded and
the side opening placed on the filter paper hole and finally 20 ul of B cell aliquot was
loaded. The cytospin technique is that after the samples were loaded the cells passed
from the containers through the filter papers holes which suck any fluid to attach on
the slides. After 3 minutes of cytospin the sample left to air dry at room temperature
for one hour. The sample then fixed in methanol for one minute, stained with eosin
for 2 minutes, stained with haematoxylin for one minute, washed with distilled water
and kept at room temperature overnight to dry. The following day the sample was
examined under the light microscope with different magnification and photographed
with a digital camera.
Cytospin and direct surface staining of cultured human B cells with anti-DR,
DP, DQ antibody
Cultured human B cells were spun at 1000 rpm for 4 minutes at 4°C and resuspended
in 2 ml of PBS. Two volumes of 134 ul of B cells (1X105 cells each) were cytospun
on Poly-L-lysine coated cells. They left at room temperature for 30 minutes to air
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dry, then fixed with acetone for 5 minutes at 4°C. They were washed with PBS
several times and one sample was incubated for 30 minutes with 100 ul (1:50
dilution in PBS) of mouse anti-human HLA class II DP, DQ, DR (Serotec). This
antibody is labelled with FITC green. The other sample was incubated for 30 minutes
with 100 ul (1:50 dilution in PBS) of mouse IgG2a negative control :FITC. This
antibody has FITC stain but does not react with human class II molecules. The slides
then were washed with PBS several times and mounted with 50% glycerol in PBS.
They were examined with light and immunofluorescence microscopy with different
magnification and photographed with a digital camera (same setting for both slides).
Cytospin and indirect surface staining of cultured human B cells with L243
antibody
Cultured human B cells were spun at 1000 rpm for 4 minutes at 4°C and resuspended
in 2 ml of PBS. Two volumes of 100 ul of B cells (1X105 cells each) were cytospun
on Poly-L-lysin coated cells. They left at room temperature for 30 minutes to air dry,
then fixed with acetone for 5 minutes at 4°C. They were washed with PBS several
times and one sample was incubated for 60 minutes with 100 ul of mouse anti-human
HLA class II L243 antibody (antibody supernatant in PRMI1640 medium - GIBCO).
The blockage of non specific binding sites was done at the same time of the antibody
incubation with 100 ul of 2% BSA in PBS. The other sample was incubated for 60
minutes with 100 ul of 2% BSA in PBS. The slides then were washed with PBS
several times and incubated for 30 minutes with 100 ul (1:50 dilution in PBS) of
goat anti-mouse IgG-FITC conjugate (sigma). Then washed with PBS several times
and mounted with 50% glycerol in PBS. They were examined with light and
immunofluorescence microscopy with different magnification and photographed
with a digital camera.
Staining of HeLa cells with anti-cytokeratin 8 antibody
HeLa cells were grown overnight on coverslips in RPMI1640 medium (GIBCO) and
provided kindly by Brian McHugh. HeLa cells are immortalized cell line and they
are human epithelial cells from a fatal cervical carcinoma transformed by human
papillomavirus 18 (HPV18). Once received the next day two coverslips were
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checked under the light microscope. Then they were washed with PBS several times,
air dried for 30 minutes at room temperature and fixed with acetone for 5 minutes at
4°C. Washed several times with PBS and permeabilized with 100 ul of 0.3% Triton
X-100 in PBS for 5 minutes at room temperature, then washed with PBS. One
coverslip was incubated for 60 minutes with 100 ul (1:100 dilution in 2% of BSA in
PBS) of mouse anti-cytokeratin 8 antibody (sigma) at room temperature and the
other coverslip was incubated for the same period with 100 ul of 2% BSA in PBS.
After several washing with PBS the coverslips were incubated for 30 minutes with
100 ul (1:50 dilution in PBS) of goat anti-mouse IgG:FITC conjugated (sigma) at
room temperature. The slides were washed with PBS several times and mounted with
50% glycerol in PBS. They were inverted up side down on a glass slides and
examined with light and immunofluorescence microscopy with different
magnification and photographed with a digital camera.
Staining of human kidney sections with anti-synaptopodin antibody
1 ml of mouse monoclonal anti-synaptopodin antibody was sent to Dr Chris Bellamy
at Edinburgh Royal Infirmary. A dilution of 1:100 of the antibody was made and it
was tested on human kidney sections with immunoperoxidase staining.
Staining of urinary sediments with anti-synaptopodin, anti-WTl and anti-
cytokeratin 8 antibodies
The urine samples (20 ml) were processed within 3-4 hours. They were spun at 2500
rpm for 5 minutes at 4°C and the urinary sediment of each sample was resuspended
in 220 ul of PBS and divided as explained below.
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20 ml of urine
spin and resuspend in 220 ul of PBS
LM& IF
20 ul was examined under light microscopy before staining to check for the presence
of cells in this sediment and photographed by digital camera. The rest of the
suspension was divided into two samples of 100 ul each. They were then cytospun
onto Poly-L-lysine coated glass slides. They were left at room temperature for 30
minutes to air dry, then fixed with acetone for 5 minutes at 4°C. They were washed
with PBS several times and permeabilized with 100 ul of 0.3% of Triton X-100 in
PBS. Then washed with PBS severai rimes and one sampie was incubated for 60
minutes with 100 ul (1:100 dilution in 2% BSA in PBS) of mouse monoclonal anti-
synaptopodin antibody (Progen) or rabbit polyclonal anit-WTl antibody (Santa Cruz
biotechnology) or mouse monoclonal anti-cytokeratin 8 antibody. The other sample
was incubated for 60 minutes with 100 ul of 2% BSA in PBS. The slides then were
washed with PBS several times and incubated for 30 minutes with 100 ul (1:50
dilution in PBS) of goat anti-mouse IgG-FITC conjugate (Sigma) or donkey anti-
rabbit IgG:PE conjugate (Santa Cruz biotechnology). Then washed with PBS several
times and mounted with 50% glycerol in PBS. They were examined with light and
immunofluorescence microscopy with different magnification (each slide was
examined in 10 minutes) and photographed with a digital camera.
Please note that the magnification provided in the figures depicting microscopy




Detection of podocyte-specific proteins mRNA in the
urine of proteinuric renal patients.
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Introduction
Podocytes or visceral epithelial cells are highly differentiated cells located on the
outer surface of the glomerular capillaries. Podocytes are terminally differentiated
cells and have limited capacity for regeneration.
Li and colleagues (2001) reported development of non-invasive method for acute
rejection by the detection of mRNA of cytotoxic proteins (perforin and granzyme B)
in the urine with reverse transcriptase polymerase chain reaction (RT-PCR). Szeto
and associates (2005) have found that urinary mRNA of Transforming Growth
Factor P (TGF-P) is correlated with renal function, the degree of histological damage
as well as intra-renal level in patients with chronic renal diseases; and this can be
used as a non-invasive investigation for the assessment of the severity of these
diseases.
Nephrin and podocalyxin mRNAs were chosen as markers for podocyte injury in
urine of proteinuric patients because they are podocyte-specific mRNAs and P-actin
mRNA was used as a positive control for total RNA extraction because it is present
in abundant amount in cells.
Because the aim was to develop a clinically useful test the samples were processed
within 3-4 hours (to be adaptable for clinical practice) without trying to preserve
mRNA by any way. Optimization has been done for every single step in the method
thereafter. This was for cDNA PCR conditions, total RNA extraction from patients




Optimization of nephrin and podocalyxin cDNA PCR conditions
PCR conditions for nephrin and podocalyxin cDNA were optimized using the control
cDNA. Three different annealing temperatures were compared for two pairs of
nephrin cDNA primers and two pairs of podocalyxin cDNA primers. The optimal
annealing temperature for HuNephlFor & HuNephlRev and HuPodolFor &
HuPodolRev was 70°C and for HuNeph2For & HuNeph2Rev and HuPodo2For &
HuPodo2Rev was 65°C (figure 3.1).























Figure 3.1. Optimization of nephrin and podocalyxin cDNA PCR conditions
1 = HuNephlFor and HuNephlRev (310 bp)
2 = HuNeph2For and HuNeph2Rev (377 bp)
3 = HuPodolFor and HuPodolRev (290 bp)
4 = HuPodo2For and HuPodo2Rev (217 bp)
cDNA PCR at 60°C
annealing temperature.
Hae III 1
cDNA PCR at 65°C
annealing temperature.
Hae III 1
cDNA PCR at 70°C
annealing temperature.
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RNA purification methods do not appear to be equal
Two different methods were used to extract total RNA from the urine of proteinuric
renal patients. The extraction was by TRIzol and Agilent total RNA isolation mini
kit. Two sets of 7 tubes of urine samples (10 ml each) with added human B cells in
the order 1 million; 500,000; 100,000; 10,000; 1000; 100; 10 went through total
RNA extraction by the two methods, treated similarly with DNasel (second method),
cDNA was synthesized with AMV-RT and finally (3-actin cDNA PCR was done. The
results showed that TRIzol method is 10-fold better than Agilent total RNA isolation
mini kit (figure 3.2).
Figure 3.2. TRIzol is better than Agilent kit in RNA purification
(P-actin cDNA PCR)
H = water control 1 = 1 million cells
2 = 500,000 cells 3 = 100,000 cells
1 = 10,000 cells 5 = 1000 cells
5 = 100 cells 7 = 10 cells
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Glycogen and tRNA are equal in total RNA precipitation
This was a trial to increase the amount of extracted total RNA by adding two
different RNA precipitants. Total RNA was extracted from two sets of 8 tubes of
urine samples with added B cells in the order 1 million; 500,000; 100,000; 10,000;
1000; 100; 10; 1. RNA was extracted by TRIzol method and in one set of dilution
was precipitated by adding glycogen and in the other by tRNA to the top layer
(aqueous phase) from chloroform stage just before isopropanol precipitation. Then it
treated with DNasel (second method) and cDNA was synthesized with AMV-RT.
P-actin cDNA PCR showed that glycogen and tRNA are equal in terms of total RNA
precipitation, but either was 10,000-fold better in comparison to the result when
neither of them was used (figure 3.3).
H 1 2 3 4 5 6 7 8 Haelll
Glycogen
H 1 2 3 4 5 6 7 8 Hae III
tRNA





H = water control
3 = 100,000 cells
6 = 100 cells
and tRNA are equal
1 = 1 million cells
4 = 10,000 cells
7 = 10 cells
total RNA precipitation
2 = 500,000 cells
5 = 1000 cells
8=1 cell
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p-actin and podocalyxin cDNA primers work on human genomic
DNA but nephrin primers do not
A dilution series of 1 ug; 0.1 ug; 0.01 ug; 0.001 ug; 0.0001 ug in 25 ul of nuclease-
free water was made from human B cells genomic DNA. 2 ul from each of them was
used for P-actin, podocalyxin and nephrin PCR. The rationale behind this was to
know whether, if the extracted RNA was contaminated with DNA, would that
interfere with the cDNA PCR results for P-actin, podocalyxin and nephrin. The
results showed positive bands in 1 ug; 0.1 ug; 0.01 ug and 0.001 ug lanes of P-actin
and 1 ug; 0.1 ug; 0.01 ug lanes of podocalyxin but no positive bands for nephrin. In
other words P-actin and podocalyxin cDNA primers work on human genomic DNA
but nephrin do not (figure 3.4).
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 Hae III
P-actin nephrin podocalyxin
Figure 3.4. p-actin and podocalyxin cDNA primers work on human genomic
DNA but nephrin do not
1 = 1 ug/25ul
2 = 0.1 ug/25ul
3 = 0.01 ug/25ul
4 = 0.001 ug/25ul
5 = 0.000 lug/25ul
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DNasel destroys all DNA in the presence of AMV-RT buffer
During RNA extraction DNA may come through as well, and that is why RNA
extraction was followed by DNasel treatment before cDNA synthesis. To test the
efficiency of DNasel, a dilution series of 1 ug; 0.1 ug; 0.01 ug; 0.001 ug; 0.0001 ug
in 5 ul nuclease-free water was made from human B cells genomic DNA and the
whole 5 ul was used instead of total RNA (second method of DNasel treatment and
cDNA synthesis). 2 ul of this reaction was used to do (3-actin, podocalyxin and
nephrin PCR. The result showed that DNasel destroyed all DNA (figure 3.5).




Figure 3.5. DNasel destroys all DNA in RNA prep
+ = positive control
1 = 1 ug/25ul
2 = 0.1 ug/25ul
3 = 0.01 ug/25ul
4 = 0.001 ug/25ul
5 = 0.0001 ug/25ul
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Heat kills DNasel before cDNA synthesis
In the second method of DNasel treatment of total RNA and cDNA synthesis both
occur in the same microcentrifuge tube. DNasel could destroy the synthesized cDNA
later if its enzymatic activity persisted. DNasel was inactivated by heat (75°C for 10
minutes).To test whether heat inactivation alone was efficient, a dilution series of
1 ug; 0.1 ug; 0.01 ug; 0.001 ug; 0.0001 ug in 5 ul nuclease-free water was made from
human B cells genomic DNA and the whole 5 ul was added instead of reverse
transcriptase (as you can see from the second method of DNasel treatment this
enzyme has been added and inactivated by heat). 2 ul of this reaction was used to do
P-actin, podocalyxin and nephrin PCR. The result showed positive bands in P-actin
and podocalyxin indicating that DNasel was completely destroyed by heat. The
added DNA gave positive PCR results (upper result) identical to the PCR results









Figure 3.6. Heat kills DNasel before cDNA synthesis
1 = 1 ug/25ul
2 = 0.1 ug/25ul
3 = 0.01 ug/25ul
4 = 0.001 ug/25ul
5 = 0.0001 ug/25ul
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 Hae III
P-actin nephrin podocalyxin
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 Hae III
P-actin nephrin podocalyxin
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MMLV-RT appears better than AMV-RT
Total RNA was extracted from two sets of 7 tubes of urine samples (10 ml each)
with added human B cells in the order 1 million; 500,000; 100,000; 10,000; 1000;
100; 10 by TRIzol methods. These samples were treated similarly with DNasel
(second method) but cDNA was synthesized differently; one set with AMV-RT and
the other set with MMLV-RT. (3-actin cDNA PCR was done and the results appeared
to show that MMLV-RT is better than AMV-RT by a factor of 10,000 (figure 3.7).
MMLV-RT
Figure 3.7. MMLV-RT appears better than AMV-RT (P-actin cDNA PCR)
H = water control 1 = 1 million cells
2 = 500,000 cells 3 = 100,000 cells
4 = 10,000 cells 5 = 1000 cells
6 = 100 cells 7 = 10 cells
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Failure ofDNasel activity explains apparent superiority of
MMLV-RT
But by testing the efficiency of DNasel (second method) in the presence of MMLV-
RT buffer it was found that positive bands are most probably DNA bands and not
cDNA. This was by doing p-actin and podocalyxin PCR on human dilution series of
human genomic DNA in the order 1; 0.1; 0.01; 0.001 and 0.0001 in 25 ul of
nuclease-free water (2 ul was used for the PCR) with and without DNasel treatment.
The results showed incomplete destruction of the DNA by DNasel in the presence of
MMLV-RT buffer and the amount of DNA was reduced by 1000 folds in
podocalyxin PCR and 10 folds in P-actin (figure 3.8). No nephrin PCR was done
because it was known from a previous experiment that its primers do not work on
human genomic DNA (see figure 3.4).












Figure 3.8. DNasel works inefficiently in MMLV-RT buffer
1 = 1 ug/25ul
2 = 0.1 ug/25ul
3 = 0.01 ug/25ul
4 = 0.001 ug/25ul
5 = 0.0001 ug/25ul
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Sensitivity of p-actin, podocalyxin and nephrin cDNA PCR
PCR sensitivity was calculated for P-actin and podocalyxin by determining how
many genomic copies could be detected by PCR.
A dilution series of 1 ug; 0.1 ug; 0.01 ug; 0.001 ug; 0.0001 ug in 25 ul of nuclease-
free water was made from human B cells genomic DNA. 2 ul (2/25th) of these
dilutions was used to do P-actin, nephrin and podocalyxin PCR (figure 3.4).
According to that the amount ofDNA used in this PCR was 80 ng; 8 ng; 0.8 ng; 0.08
ng and 0.008 ng. Because 1 ng of DNA contains approximately 330 copies of the
genome, and P-actin PCR was positive in the first four lanes (1 ug; 0.1 ug; 0.01 ug
and 0.001 ug), the number of genomic copies in the positive lanes of P-actin PCR
was 26400; 2640; 264 and 26 copies and the last figure is the PCR sensitivity of P-
actin.
Podocalyxin PCR gave positive bands in the first three lanes (1 ug; 0.1 ug and 0.01
ug). So, the number of genomic copies was 26400; 2640; 264 copies and the last
figure is the PCR sensitivity of podocalyxin.
Nephrin PCR was negative so the sensitivity could not be calculated using this
method.
Nephrin PCR was negative so the sensitivity could not be calculated using this
method.
This was calculated as below:
... Human genome = 3X109 bp
... Molecular weight of bp = 629 Dalton
.'. Molecular weight of human genome = 3X109 X 629 Dalton
... Avogadro number (6X1023) = 3X109 X 629 g = 3X109 X 629 X1012pg
.'. Human genome = 3X109 X 629 X1012
6X1023
= 3 pg . .1 ng contains 330 genomic copies
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Patients results
Seventy urine samples were collected from seventy renal patients with proteinuria.
All of these samples were negative for nephrin and podocalyxin cDNA PCR after the
optimization steps described above. Many samples gave positive P-actin cDNA PCR
results (figure 3.9) and the control human kidney cDNA consistently gave positive
results.
H 1 2 3 4 5 6 Haelll
Figure 3.9: PCR of urinary p-actin cDNA of proteinuric patients
A band is seen at the predicted size of 150bp in lanes 2, 3, 4 and 6. Weak bands are





The podocyte is increasingly implicated in proteinuric renal diseases, from minimal
change nephrotic syndrome and FSGS, to more overtly immunologically mediated
diseases such as membranous nephropathy. It is also suspected of involvement in
progressive renal disorders involving focal glomerular scar formation, such as the
FSGS associated with obesity and HIV infection.
Renal biopsy is still the gold standard for the diagnosis of glomerular diseases, but is
invasive and is not without complications. It was proposed to develop a non-invasive
investigation of proteinuric renal patients by the detection of podocyte injury markers
in their urine.
This was by total RNA extraction from patients urine and RT-PCR of nephrin and
podocalyxin mRNAs which was chosen as podocyte injury markers to study and
correlate that with the degree of podocyte injury on the renal biopsy of the same
patients.
Li and colleagues (2001) described non-invasive technique for the diagnosis of acute
renal allograft rejection by detection of mRNA of cytotoxic proteins in urinary cells
with RT-PCR. It has also been reported in an abstract that podocyturia can be
detected with reverse transcriptase quantitative polymerase chain reaction on nephrin
mRNA (McBryde et al., 2002). A correlation has been reported between urinary
mRNA of TGF-(3 and renal function in patients with chronic renal diseases (Szeto et
al., 2005). Petermann and associates (2003) reported the detection of mRNA of
podocyte-specific proteins in urine from rats with experimental membranous
nephropathy.
In the first instance total RNA was extracted from patients urine samples by TRIzol
method and treated with DNasel, cDNA was synthesized with AMV-RT and finally
cDNA PCR was done for (3-actin, podocalyxin and nephrin but the results were
inconclusive.
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Because of the inconclusive results a decision was made to optimize every single
step in the method to see whether the results were negative due to improper method
or there were no podocyte injury markers to be detected in the urine.
Total RNA extraction was compared between two methods; TRIzol and Agilent total
RNA isolation mini kit. This was from cultured human B cells added to 10 ml of
urine samples in the order lmillion; 500,000; 100,000; 10,000; 1000 and 10 cells. It
was found that TRIzol was better where P-actin cDNA was positive in lmillion;
500,000 and 100,000 lanes for TRIzol and positive only in 1 million lane in Agilent
total RNA isolation mini kit (figure 3.2). Groningen and co-workers (2004) reported
higher total RNA extraction with TRIzol method than NP40-based solution method
and RNeasy spin columns (from Qiagen).
This was improved considerably when two RNA precipitants were compared at the
isopropanol precipitation step (TRIzol method) to increase the extracted amount.
Glycogen and tRNA were compared in two sets of samples (as above) and both were
similar because P-actin cDNA was positive up to 1 cell lane in the two sets (figure
3.3).
A dilution series of human genomic DNA was used to answer three questions.
Firstly, do P-actin, nephrin and podocalyxin cDNA primers work on human DNA?
This was important because DNA can be extracted during RNA preparation and may
interfere with interpretation of cDNA PCR results. This was done because it was not
known if these primers cross an intron or not, because if they do not they will work
on both cDNA and DNA to produce an identical band size. P-actin and podocalyxin
PCR were positive but nephrin PCR was negative (figure 3.4). It was noticed that
nephrin PCR was positive with human kidney cDNA (positive control), but it did not
give any positive results with urine samples or human genomic DNA. This is
probably because nephrin cDNA primers cross an intron and work only on the
cDNA. Secondly, does DNasel destroy all genomic DNA in the RNA preparation in
the presence of AMV-RT buffer? This is important because the presence of genomic
DNA will interfere with the PCR results as we can see from the above. To test that
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the same DNA dilution series was used instead of total RNA and treated with
DNasel. P-actin and podocalyxin PCR were negative confirming that DNasel
destroyed all DNA (figure 3.5). Thirdly, does heat inactivate DNasel? This is
important because if DNasel stays in the reaction it may destroy the cDNA later.
DNasel was heated with heat then the same DNA dilution was added instead of RT.
P-actin and podocalyxin PCR were positive and identical to PCR results without
DNasel treatment (figure 3.6), confirming that the heating protocol used completely
inactivated DNasel.
AMV-RT and MMLV-RT were compared on two sets of urine samples with added B
cells (as above). Total RNA was extracted with TRIzol and treated with DNasel.
cDNA synthesis was with AMV-RT in one set and MMLV-RT in the other set.
P-actin cDNA was positive in the 1 million and 500,000 lanes of AMV-RT and till
10 cells lane ofMMLV-RT (figure 3.7). But there was a question; are these cDNA or
DNA bands? DNasel treatment and cDNA synthesis take place in the same
microcentrifuge tube and at that time we knew DNasel works in AMV-RT buffer
(figure 3.5), but we did not know if it works in MMLV-RT buffer or not. To test that
P-actin and podocalyxin PCR were done on human DNA dilution series in the order
1 ug; 0.1 ug; 0.01 ug; 0.001 ug and 0.0001 ug in 25 ul of nuclease-free water with
and without DNasel treatment in the presence of MMLV-RT buffer (figure 3.8).
P-actin and podocalyxin PCR were positive in the first four lanes without DNasel
treatment, but with DNasel treatment it decreased by 10 folds in p-actin PCR
(positive in the first three lanes) and by 1000 folds in podocalyxin PCR (positive in
the first lane). Although DNasel was not efficient in the presence of MMLV-RT
buffer, it can be concluded that the PCR result will be cDNA if the P-actin and
podocalyxin bands are similar but DNA if the P-actin bands are stronger. It has been
described that cDNA synthesis with AMV-RT is better than Superscript; which is
MMLV-RT from Invitrogen (Groningen et al., 2004).
The last step was to measure the sensitivity of P-actin and podocalyxin PCRs, and it
was found that P-actin PCR is 10 fold more sensitive than podocalyxin PCR. By
looking at p-actin cDNA PCR results (figure 3.3), it is clear that it is sensitive up to 1
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cell in two sets of cells in the experiment. The difference between P-actin DNA and
cDNA PCRs may be argued that more mRNA copies are expected to be present in
one cell. Based on this observation podocalyxin cDNA PCR should give positive
signals when 10 podocytes are present in patients urine which sensitive enough to
detect the number of urinary podocyte reported in literature (table 1.1 and table 1.2).
In conclusion, TRIzol is better than Agilent total RNA isolation mini kit for total
RNA extraction, glycogen and tRNA are similar for total RNA precipitation, DNasel
works better in AMV-RT buffer than MMLV-RT buffer, (3-actin and podocalyxin
cDNA primers work on human genomic DNA but nephrin do not, DNasel kills all
DNA in the RNA preparation, and heat completely destroys DNasel .The PCR is
sensitive enough for P-actin and podocalyxin.
After all of the previous optimization, and having a sensitive method, urine PCR
results were all negative for podocyte mRNAs although many of these urine samples
gave positive results for P-actin cDNA PCR as well as the human kidney cDNA
which was consistently positive. The question therefore became whether the
podocyte mRNA had been degraded before it could be detected during urine storage
in the urinary bladder and the time in the outpatient department till processed, or
whether there were no podocytes in the urine. Whatever the answer to this question,
this method did not appear to be useful as a diagnostic investigation for proteinuric
renal patients due to its persistent negativity, although some high risk patients were
included randomly in the study.
I therefore went on to do urine immunofluorescence studies with podocyte protein
antibodies (synaptopodin and WT1 antibodies) to answer the question and to assess




Detection of podocytes and/or their fragments in the
urinary sediment of proteinuric renal patients.
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Introduction
As described in chapter 1, the evidence for the central role of the podocyte in the
development of diseases associated with glomerular proteinuria is now very
substantial.
Detection of urinary podocytes and/or their fragments with immunofluorescence
(using anti-podocalyxin antibody) in the urine of patients with acute
glomerulonephritis has been reported by one group to reflect disease activity (Hara et
al., 1995 and Hara et al., 1998). Podocytes have been also detected in the urine of
rats with experimental membranous nephropathy (Petermann et al., 2003) and
experimental diabetic nephropathy (Petermann et al., 2004).
The podocyte antibody (anti-synaptopodin antibody) was chosen to be used in this
immunofluorescence study for staining of urinary sediment of proteinuric patients in
a trial to detect podocytes. Anti-podocalyxin antibody was not used, because it could
react with platelets and other cells.
This study was conducted to explain why the mRNA of podocyte proteins was
undetectable in the urine of proteinuric renal patients according to the results in
chapter 3, and to know whether the results were negative because there were no
podocytes in patients urine or due to other reasons.
The other aim of this study was to test the validity of detecting urinary podocyte with
immunofluorescence technique as it was published as a potential non-invasive
diagnostic and predictive method for the glomerular disease.
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Results
Indirect surface staining of cultured human B cells
The rationale of this experiment was to validate the indirect immunofluorescence
technique. Two samples of cultured human B cells (1X106 cells each) were involved
in this experiment. The first sample was stained with primary and secondary
antibodies and the second sample was used as a negative control. The results showed
positive staining of B cells with immunofluorescence microscope in the first sample
and B cells with light microscope and no staining with immunofluorescence




Figure 4.1: Indirect surface staining of cultured human B cells
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Cytospin of cultured human B cells and staining with Haematoxylin
and Eosin
The rationale of this experiment was to learn the cytospin technique and to check the
capability of cells to attach to Poly-L-lysine coated glass slides. 20 ul of B cells
aliquot in PBS (contains 1X105 cells which is the optimal number for good cytospin
results) was cytospun and stained with haematoxylin and eosin. Figure 4.2 shows a
light microscope picture of haematoxylin and eosin stained B cells confirming that
cells can be attached, fixed and stained on Poly-L-lysine coated slides.
(20X magnification)
Figure 4.2: Cytospin of cultured human B cells and staining with Haematoxylin
and Eosin
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Cytospin and direct surface staining of cultured human B cells with
fluorescence anti-DR, DP, DQ antibody (single layer)
The rationale of this experiment was to validate the cytospin and direct
immunofluorescence technique. Two samples of cultured human B cells (1X105 cells
each) were involved in this experiment. The first sample was stained with the
antibody and the second sample was used as a negative control. The results showed
positive staining of B cells with immunofluorescence microscope in the first sample
and B cells with light microscope and no staining with immunofluorescence






Figure 4.3: Cytospin and direct surface staining of cultured human B cells with
anti-DR, DP, DQ antibody
98
Cytospin and indirect surface staining of cultured human B cells
with L243 antibody (double layer)
The rationale of this experiment was to validate the cytospin and indirect
immunofluorescence technique. Two samples of cultured human B cells (1X105 cells
each) were involved in this experiment. The first sample was stained with primary
and secondary antibodies and the second sample was used as a negative control. The
results showed positive staining of B cells with immunofluorescence microscope in
the first sample and B cells with light microscope and no staining with
immunofluorescence microscope in the negative control sample (figure 4.4).








Figure 4.4: Cytospin and indirect surface staining of cultured human B cells
with L243 antibody
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Staining ofHeLa cells with anti-cytokeratin 8 antibody
This experiment was done to test anti-cytokeratin 8 antibody on epithelial cells
(HeLa cells) which are rich in cytokeratin8. This antibody was used as a positive
control for the urinary sediment in this study, because this antibody stains epithelial
cells in the urine. HeLa cells were grown on coverslips. One sample was stained with
the primary and secondary antibodies and the other one was used as a negative
control. The results showed positive staining for the positive sample and HeLa cells










Figure 4.5: Staining of HeLa cells with anti-cytokeratin 8 antibody
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Staining of human kidney sections with anti-synaptopodin and
anti-CD2AP antibodies
This experiment was done to test anti-synaptopodin and anti-CD2AP antibodies on
human kidney sections. This was done by Dr Chris Bellamy at Edinburgh Royal
Infirmary. The results showed strong positive staining of the podocytes and weak
staining of the arteriolar lining with anti-synaptopodin antibody (figure 4.6). Anti-
CD2AP antibody showed non specific staining (has not been photographed).
Anti-synaptopodin antibody
Figure 4.6: Staining of human kidney sections with anti-synaptopodin antibody
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Staining of urinary sediments with anti-cytokeratin 8 antibody
This experiment was done to check if cells from urine could be cytospun and stained.
10 samples (20 ml) of urine were collected and tested before and after staining (see
method). The results showed (6 samples gave positive results) that cells can be seen
under the light microscope before staining. Urinary epithelial cells stained positive
for the antibody and the same field was visualised by light microscopy. Negative































Staining of urinary sediments with anti-synaptopodin antibody
100 samples (20 ml each) of urine were collected and stained with anti-synaptopodin
antibody. Only one sample was positive. In this result it can be seen that urinary cells
are detected before and after staining. The positive slide shows positive
immunofluorescence of a urinary cell and the negative control slide shows only










Figure 4.8: Staining of urinary sediments with anti-synaptopodin antibody
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Patients results
After examining 100 urine samples, only one sample gave positive result with anti-
synaptopodin antibody and all of them were negative for anti-WTl antibody.
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Discussion
Podocytes are injured in different forms of experimental and human
glomerulopathies, including minimal change nephrotic syndrome, FSGS,
membranous glomerulonephritis, diabetic nephropathy and lupus nephritis.
As described in the chapter 3 it was proposed to develop a non-invasive investigation
for proteinuric renal patients by the detection of urinary podocyte protein mRNA by
RT-PCR, but the result of 70 urine samples were negative.
In this study I was trying to achieve two goals; the first one to know whether the 70
samples were negative because there were no urinary podocytes or due to other
reasons. The second goal was to develop a non-invasive investigation for glomerular
renal diseases.
This was by immunofluorescence study of patients urinary sediments to detect
podocytes using a monoclonal antibody against synaptopodin (an actin associated
protein expressed in podocytes and hippocampal cells) and polyclonal antibody
against WT1 (podocyte nuclear protein).
A non-invasive technique for the diagnosis of podocyte shedding was developed by
Hara and colleagues (1995), by examining the urinary sediment of patients with
different renal diseases with immunofluorescence using monoclonal antibody against
podocalyxin (a glycoprotein prominently expressed on podocytes). Urinary
podocytes had been identified and grown in culture from rats with experimental
membranous nephropathy (Petermann et al., 2003) and experimental diabetic
nephropathy (Petermann et al., 2004).
The majority of urinary podocytes evidence mostly came from the same group
(e.g. Hara et al., 1998) using the same anti-podocalyxin antibody which can be
expressed by vascular endothelial cells (Horvat et al., 1986), platelets (Miettinen et
al., 1999) and haemopoietic stem cells (Doyonnas et al., 2001). Because of these
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reasons more specific podocyte antibodies were sought including anti-synaptopodin,
anti-CD2AP and anti-WTl.
Anti-synaptopodin and anti-CD2AP antibodies were tested on podocytes on human
kidney section and anti-CD2AP was excluded because it was widely expressed. Anti-
synaptopodin and anti-WTl antibodies were used together because the first antibody
is an intracytoplasmic and the second antibody is a nuclear antibody and if any urine
sample stained positive then it can be judged whether this was a whole podocyte,
nuclear or other fragment. A further step was planned to be taken place if any
positive results appeared which the study of the viability of these cells and the most
important the relation between urinary podocytes and the renal biopsy results of the
same patients.
The method of this study was fixed by showing that B cells can be cytospun, fixed
and stained on Poly-L-lysine coated glass slides. Very importantly also the
cytokeratin 8 antibody positive control experiment showed that urinary cells can be
cytospun, fixed and stained on Poly-L-lysine coated glass slides. Anti-cytokeratin 8
antibody was used because it stains epithelial cells which are expected to be found in
the urine.
Although different cell types were found in all 100 urine samples, including tubular
epithelial cells, squamous epithelial cells and red blood cells as wells as bacteria,
only one urine sample stained positive for synaptopodin. All of the samples were
negative for anti-WTl antibody staining.
An irrelevant isotype control primary antibody was not employed to determine the
specificity of staining in the immunofluorescence studies and this is an important
caveat in the interpretation of the findings presented.
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The results of urinary podocytes contrast with those reported by Hara and colleagues
(1995 and 1998). This could be partly because they examined selected high risk
patients, but it may also be relevant that podocalyxin can be found on platelets and
elsewhere.
In conclusion, podocyte mRNA could not be detected because there were no
podocytes in the urine. This immunofluorescence technique is not a good non¬
invasive investigation and one more set of experiments was undertaken to confirm
the validity of this conclusion (chapter 5).
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Chapter 5
Control experiments on podocytes
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Introduction
The experiments in this chapter were a collaboration between our group and the renal
unit at Southmead Hospital in Bristol. Professor Peter Mathieson and Dr Moin Saleem
provided cultured human podocytes and lab space to do these control experiments.
These experiments were conducted to test the techniques used for urinary podocyte
mRNA extraction (chapter 3) and immunofluorescence (chapter 4) studies after the
negative results which were recorded. So, the question here was to know whether
these techniques were working or not.
109
Results
Staining of podocytes on coverslips with anti-synaptopodin antibody
The rationale of this experiment was to test anti-synaptopodin antibody on human
cultured podocytes (AB-NT) before spiking the urine with podocytes in the following
experiments. Podocytes were stained on coverslips with primary and secondary
antibodies. The result shows positive cytoplasmic staining (figure 5.1).
(20X magnification)
Figure 5.1: Staining of podocytes with anti-synaptopodin antibody on coverslips
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Spiking of urine with podocytes and staining with anti-synaptopodin
antibody
This experiment was conducted to test whether podocytes can be cytospun on Poly-L-
lysine coated slides, fixed and stained with anti-synaptopodin antibody (with same
method in chapter 4). Podocytes growing on coverslips were scraped off and
resuspended in RPMI media and podocyte dilutions were made to contain
approximate number of: 32, 16, 8, 4, 2 (3 samples) and 1 (5 samples). These dilutions
were added to 1 ml of urine, cytospun and stained with anti-synaptopodin antibody.
The results showed only a small proportion of podocytes could be identified; 3 cells in
32 cells slide, 1 cell in 16 cells slide, 1 cell in 8 cells slide, 1 cell in 4 cells slide, 1 cell
in one of 2 cells slides and 1 cell in one of 1 cell slides. This amounts to 10-20% of




Figure 5.2: Staining of spiked urinary podocytes with anti-synaptopodin
antibody
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Spiking of PBS with HeLa cells and staining with anti-cytokeratin 8
antibody
When the number of positive podocytes was low in the last experiment it was decide
to apply the same technique on HeLa cells and staining with anti-cytokeratin 8
antibody as a control experiment. HeLa cells were growing in tissue culture flask and
dilutions were made to contain approximate number of: 32, 16, 8, 4, 2 (3 samples) and
1 (5 samples). These dilutions were added to 1 ml of PBS because anti-cytokeratin 8
antibody stains epithelial urinary (figure 4.7), cytospun and stained with anti-
cytokeratin 8 antibody. The results showed 8 cells in 32 cells slide, 3 cells in 16 cells
slide, 2 cells in 8 cells slide, 1 cell in 4 cells slide, 1 cell in one of 2 cells slides and 1
cell in one of 1 cell slides. Again this amounted to identification of only 10-20% of
the cells that were originally added to the samples. HeLa cells also showed changed
morphology (figure 5.3)
(20X magnification)
Figure 5.3: Staining of spiked HeLa cells in PBS with anti-cytokeratin 8 antibody
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Spiking of urine with podocytes and RNA extraction: urinary
podocyte mRNA method appears to be working
The rationale of this experiment was to test the technique used for podocytes mRNA
extraction from patients urine after the negative results had been recorded. Another
set of podocyte dilutions; 32, 16, 8, 4, 2 (3 samples) and 1 cell (5 samples) were
added to 1 ml of urine each and went through TRIzol RNA extraction technique (with
same method in chapter 3). This was followed by nephrin, podocalyxin and P-actin
cDNAs PCR. Results were positive for the three PCRs and for all samples (figure
5.4).
H + 1 2 3 4 5 6 7 8 9 10 11 12 Hae III
***** ** m. a - * « s
nephrin
H + 1 2 3 4 5 6 7 8 9 10 11 12 Hae III
podocalyxin
H + 1 2 3 4 5 6 7 8 9 10 11 12 Hae III
P-actin
Figure 5.4: PCR of spiked urinary podocytes cDNAs
H= waster control
1= 32 cells sample
3= 8 cells sample
5= 2 cells sample
7= 2 cells sample
9= 1 cell sample
11= 1 cell sample
+= positive control (human kidney cDNA)
2= 16 cells sample
4= 4 cells sample
6= 2 cells sample
8= 1 cell sample
10= 1 cell sample
12= 1 cell sample
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Why all samples were positive for nephrin, podocalyxin and p-actin
cDNAs PCR? Perhaps due to contamination
RNA extraction reagents were though to be contaminated either at the time of making
podocyte dilutions in Bristol or during the rest of experiment in Edinburgh. It was
decided to apply the same technique on B cell and nuclease free water (same water
used in the previous experiment). This was followed by podocalyxin cDNA PCR on
the product of B cells, water, sample 32 and sample 16. The results were positive for
the first two samples and negative for the other two (figure 5.5).
HI 2 3 4 Hae
Podocalyxin
Figure 5.5: Podocalyxin cDNA PCR
H= waster control
1= 32 cells sample
2= 16 cells sample




The experiments in this chapter were undertaken to prove the validity of the
conclusion of chapter 4 about the usefulness of urinary podocytes as a diagnostic tool.
This was by testing the validity of the techniques used in chapter 3 and chapter 4
themselves. These experiments were done between Bristol and Edinburgh.
Although anti-synaptopodin antibody was proved to be working on human podocytes
(figure 4.6) it was very important to test it on AB-NT podocytes grown on coverslips
before spiking urine with these podocyte dilutions.
An irrelevant isotype control primary antibody was not employed to determine the
specificity of staining in the immunofluorescence studies and this is an important
caveat in the interpretation of the findings presented
After anti-synaptopodin antibody was proved to work on podocytes; they were
scraped off coverslips and resuspended in RPMI media then two sets of podocyte
dilutions were made to contain the approximate number of: 32, 16, 8, 4, 2 (3 samples)
and 1 (5 samples). The dilutions were made to test the technique sensitivity.
One set of podocyte dilutions was added to 1 ml of urine each; cytospun on Poly-L-
lysine coated slides and stained with anti-synaptopodin antibody. Analysis showed
antibody positive cells of much changed morphology, but only 8 of about 70 cells
were detected by immunofluorescence microscopy.
A control experiment was done on HeLa cells using the same method and staining
with anti-cytokeratin 8 antibody. HeLa cells were growing in tissue culture flask were
trypsinised and resuspended in RPMI media. The dilutions were added to PBS
because anti-cytokeratin 8 antibody stains urinary epithelial cells (figure 4.7). The
results again showed different morphology and similarly only 10-20% of cells were
detected by immunofluorescence microscopy.
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So, the immunofluorscence technique used to stain podocytes in the urine of
proteinuric patients does work, but detected only 10-20% of the actual number of cells
added to the preparation.
Because this technique is similar to the technique used in the original paper by Hara
and colleagues (1995), which described urinary podocytes in renal patients, and in the
following papers by the same group; a point can be raised about the actual number of
podocytes they described in their publication and the correlations they made between
urinary podocyte numbers and renal disease severity as well as correlation with
different drugs.
Also the loss is more in the low dilution samples and this may be raise the possibility
that patient gave negative results may have low number of podocytes in their urine
which can not be detected.
It has been noticed that the pattern of immunofluorescence staining and morphology
change when cells go through cytospin machine. By looking at AB-NT podocytes
(figure 5.1) and HeLa cells (figure 4.5) on coverslips a well defined cell shape and
immunofluorescence staining can be seen which changes after the cytospin (figure 5.2
and figure 5.3). This was similar to the immunofluorescence pattern of the only
podocyte detected by anti-synaptopodin antibody from patient urine (figure 4.8)
The other set of podocyte dilutions was used for RNA extraction and reverse
transcription followed by PCR for nephrin, podocalyxin and P-actin cDNAs.
Unexpectedly all samples were positive for the three PCRs (expected to get some
negative results especially in the low number dilutions) and furthermore all have the
same band intensity.
This made us suspicious of contamination. A control experiment was done using B
cells and water (same water used in the original experiment) which went through the
same procedure for RNA extraction, with the same reagents, but in a different lab:
these were negative.
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I was wondering about the possibility of samples contamination at the time of making
podocyte dilutions. So a plan was made to do a repeat control experiment for RNA
extraction technique on another set of AB-NT podocyte dilutions which can be
provided kindly by our collaborators in Bristol.
In conclusion, immunofluorescence technique works but detects only 10-20% of cells.




Production and microinjection of podocyte construct
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Introduction
The podocyte is a terminally differentiated cell and located on the outer surface of
the GBM. It plays a crucial role in the glomerular filtration process and hence its
injury associated with loss of protein in urine.
Specific cell ablation is a useful method for cell function analysis in vivo. Saito and
colleagues (2001) developed a conditional cell ablation in transgenic mice, called
toxin receptor-mediated cell knockout. This was by expressing human diphtheria
toxin receptor (hDTR) on the hepatocytes of transgenic mice using the plasmid
pMS7 which contains hepatocyte-specific promoter (albumin) and hDTR gene.
Specific cell ablation was also reported in macrophages by Cailhier and collaborators
(2005) who generated transgenic mice expressing hDTR specifically on
macrophages. Mice are naturally insensitive to the effects of diphtheria toxin (DT).
DT is produced by Corynebacterium diphtheriae as a single polypeptide that is
proteolytically cleaved into a two-chain protein. After intra-muscular injection in
transgenic mice it binds to its membrane receptor, which is human Heparin Binding-
Epidermal Growth Factor; (hHB-EGF) by the larger B-subunit and then internalized.
The smaller A-subunit dissociates in acidic endosome and pass to the cytoplasm
where it becomes catalytically active and ADP-ribosylates elongation factor 2 (EF2)
and inactivate protein synthesis (Richard, 2001)
Several podocyte specific promoters have been mooted. Wong and colleagues (2000)
reported that a human 1.25 kb nephrin gene fragment can lead to podocyte specific
expression of LacZ in transgenic mice. Moeller and associates (2000) have shown
that two murine 8.3 kb and 5.4 kb nephrin gene fragments can direct the expression
of LacZ in podocytes and the brain in transgenic mice. Human 2.5 kb Podocin and
murine 1.25 kb nephrin gene fragments were found to lead to podocyte specific
expression of p galactosidase in transgenic mice (Moeller et al., 2002).
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The strategy of this study was to test primers for the murine nephrin gene fragment
described by Moeller and collaborators (2002) by Taq DNA polymerase and produce
this fragment with Vent DNA polymerase. This is because it has low base insertion
error (57 per million base insertion in comparison to Taq DNA polymerase which
has error rate of 285 per million bas insertion) and to produce blunt ended PCR
product. The blunt ended PCR product would then be subcloned into pCR®4Blunt-
Topo, the PCR product then digested with NotI and BamHI restriction enzymes and
subcloned into the plasmid pMS7 to produce the podocyte specific construct (the
plasmid pIN). The microinjection of the podocyte construct into murine fertilized
ova would hopefully lead to generation of transgenic mice expressing hDTR on
podocytes.
In this study it was proposed to induce a specific podocyte injury with DT in hDTR
transgenic mice (if they were successfully generated) and study the podocyte,
glomerular and renal consequences.
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Results
Verification of the plasmid pMS7
This plasmid was used for generation of transgenic mice expressing hDTR
specifically on hepatocyte (Saito et al., 2001). Midipreparation of the plasmid was
performed from transformed E.coli and it was tested with 4 different restriction
enzyme analyses according to the accompanying map (EcoRI, PstI, BamHI& Bglll,
and BamHI&Kpnl). The results (figure 6.1) show some bands with unexpected size
(full sequencing later showed non-included restriction sites in the original map), but
when the plasmid was sequenced with M13For and M13Rev primers the results
showed that NotI restriction site (M13Rev) is identical to murine albumin
enhancer/promoter and Xhol/Sall restriction site (M13For) is identical to rabbit |3-
globin/polyA (figure 6.2). This means that the correct pMS7 plasmid has been
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Figure 6.2: Restriction enzyme analysis and sequencing map of pMS7
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Production of murine nephrin gene fragment (podocyte promoter)
with polymerase chain reaction
The murine nephrin gene fragment (podocyte promoter) was produce to replace
murine albumin (hepatocyte promoter) in the plasmid pMS7 and induce specific
podocyte injury using DT. This was performed with Taq DNA polymerase and Vent
DNA polymerase (see discussion for details). The results showed a strong DNA band
of the expected size of 1315 bp (figure 6.3).





Figure 6.3: Nephrin gene fragment PCR
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Subcloning of the nephrin gene fragment into pCR®4Blunt-Topo
and production of pCR4BN
The nephrin gene fragment was subcloned into pCR4®Blunt-Topo to be able to
sequence the fragment. E.coli was transformed with pCR4BN. Minipreparation and
midipreparation were tested by restriction enzyme working on pCR4BN (EcoRI) and
restriction enzymes working on nephrin gene fragment (NotI and BamHI). The
results showed DNA band of the expected size of 1315 bp (figure 6.4). DNA was












figure 6.4: Enzyme restriction analysis of pCR4BN DNA minipreparation and
nidipreparation
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Subcloning of the nephrin gene fragment from pCR4BN into pMS7
and production of pIN (podocyte construct)
The podocyte construct (pIN) was produced by subcloning the nephrin promoter
fragment from pCR4BN into pMS7. E.coli was transformed with the plasmid pIN
and minipreparation, midipreparation and maxipreparation of its DNA was done.
Enzyme restriction analysis was performed on all pIN DNA preparations (NotI and
BamHI). The results showed DNA band of the expected size of 1315 bp (figure 6.5).
Sequencing was done of all components of pIN using the primers illustrated in figure
2.1 and it was proved to consist of murine nephrin gene fragment (podocyte
promoter), rabbit P globin intron, hHB-EGF cDNA (hDTR gene), rabbit P


















Figure 6.6: pIN map
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Mice genotyping primers work on pIN DNA but not wild type mouse
DNA
This experiment was done to design and optimize a genotyping PCR method for the
genomic DNA of the potentially transgenic mice after the microinjection of the
podocyte construct. This was to test murine DNA for the expression of pIN nephrin
gene fragment and rabbit (3 globin intron using pINPCR-Forl and pINPCR-Revl
primers (nephrin gene/intron genotyping) and for the expression of hDTR using
pINPCR-For2 and pINPCR-Rev2 primers (hDTR gene genotyping). These two sets
of primers were tested on a dilution series of pIN DNA in the order 10 ng/ul, 1 ng/ul,
0.1 ng/ul, 0.01 ng/ul, 0.001 ng/ul and 0.0001 ng/ul and wild type mouse DNA. The
results showed positive results in both PCRs in all dilutions of pIN DNA at 50°C
annealing temperature. The results also showed negative results in both PCRs with
wild type mouse DNA (figure 6.7).
pIN DNA Wild type mouse DNA
Expected band
size is 243 bp
HI 2 3 4 5 6 Haelll
nephrin gene/intron genotyping
Hae III
pIN DNA Wild type mouse DNA
Expected band
size is 228 bp
HI 2 3 4 5 6 Hae III
hDTR gene genotyping
Hae III
Figure 6.7: Optimization of genotyping PCRs
H = water control 1 = 10 ng/ul 2=1 ng/ul
3 = 0.1 ng/ul 4 = 0.01 ng/ul 5 = 0.001 ng/ul
6 = 0.0001 ng/ul
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Genotyping PCRs for the potentially transgenic mice DNA
Two genotyping PCRs (nephrin gene/intron and hDTR gene) were done on the
purified potentially transgenic mice DNA. The results showed no band in the water
control lane, positive band in the positive control (pIN DNA) lane, and no correct
band size in the negative control DNA (wild type mouse DNA) or in any of the 69
DNA samples of the potentially transgenic mice DNA. Only 1-16 samples are





H + - 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Hae III
nephrin gene/intron genotyping
Expected band
size is 228 bp
+ - 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Hae III
hDTR gene genotyping
Figure 6.8: The potentially transgenic mice genotyping (16 samples)
H = Water control
+ = Positive control (pIN DNA)
- = Negative control (wild type mouse DNA)
1-16 = the potentially transgenic mice DNA
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Genotyping PCRs for the potentially transgenic mice DNA with
different annealing temperature.
The rationale for this experiment was to test different annealing temperature of these
PCRs using two of the potentially transgenic mice DNA samples. The results showed
hDTR gene genotyping primers do not work at 55°C and 60°C annealing temperature
and no positive results in terms of genotyping (figure 6.9).
50°C 55°C 60°C
+ - 1 2 H Hae III + - 1 2 H Hae III + - 1 2 H Hae III
nephrin gene/intron genotyping
50°C 55°C 60°C
+ - 1 2 H Hae III + - 1 2 H Hae III + - 1 2 H Hae III
hDTR gene genotyping
Figure 6.9: Genotyping PCRs with different annealing temperature
+ = Positive control (pIN DNA)
- = Negative control (wild type mouse DNA)
H = Water control
1-2 = the potentially transgenic mice DNA
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Genotyping PCRs for the potentially transgenic mice DNA with low
magnesium concentration
The rationale for this experiment was to test if low magnesium concentration will
increase the specificity of the genotyping PCRs. 0.5 ul of 25 mM MgC12 was added
instead of 1 ul to the PCRs reagents. The results showed positive control band and no
expected bands in the negative control and two samples of the potentially transgenic
mice DNA in both PCRs. Also no bands in water control lane (figure 6.10).
H + - 1 2 Hae III
nephrin gene/itron genotyping
H + - 1 2 Hae III
hDTR gene genotyping
Figure 6.10: Genotyping PCRs with low magnesium concentration
H = Water control
+ = Positive control (pIN DNA)
- = Negative control (wild type mouse DNA)
1-2 = the potentially transgenic mice DNA
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Genotyping PCRs for the potentially transgenic mice DNA with 40
cycles
The rationale for this experiment was to test if increasing PCRs cycles from 30 to 40
will get them work by increasing sensitivity. The results showed positive control
band and no expected bands in the negative control and two samples of the
potentially transgenic mice DNA of both PCRs. Also no bands in the water control
lane (figure 6.11).
H + - 1 2345 67 89 10 11 12 13 14 15 16 Hae III
nephrin gene/intron genotyping
H + - 1 234567 89 10 11 12 13 14 15 16 Hae III
hDTR gene genotyping
Figure 6.11: Genotyping PCRs with 40 cycles
H = Water control
+ = Positive control (pIN DNA)
- = Negative control (wild type mouse DNA)
1-16 = the potentially transgenic mice DNA
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Control PCR for the potentially transgenic mice DNA genotyping
PCR
The rationale for this experiment was to test whether the amount of the potentially
transgenic mice DNA was adequate for the genotyping PCRs to work. This was done
using collagen IV a3 primers (4A3WTR and 4A3KOWTL); the wild type (control)
primers used for genotyping COL4A3 knockout mice and the potentially transgenic
mice DNA. All 69 samples of the potentially transgenic mice DNA gave the
expected band size (1000 bp) for PCR showing that the amount of DNA was
adequate for PCR. A strong band is seen without any extra artefact bands showing
that the multiple DNA bands in genotyping PCRs are primer specific. The results
below show 17 of 69 samples (figure 6.12)
H + 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Hae III
Figure 6.12: Control PCR for the potentially transgenic mice DNA genotyping
PCR
H = Water control
+ = Positive control (wild type mouse DNA)
1-17 = the potentially transgenic mice DNA
132
Spiking of the potentially transgenic mice DNA with pIN DNA
This experiment was done to test whether the multiple DNA bands in the genotyping
PCRs consume the genotyping primers and prevent them from working. A dilution
series of 0.01 ng/ul, 0.001 ng/ul, 0.0001 ng/ul and 0.00001 ng/ul from pIN DNA was
used to make 1:1 dilution with the potentially transgenic mice DNA (200 ng) and
nuclease-free water. These two dilutions were used for the two genotyping PCRs.
The results showed that spiking the potentially transgenic mice DNA with pIN DNA
gave positive results for the construct and these multiple bands did not consume the
primers (figure 6.13).
Water dilution Wild type mouse DNA dilution
H 1 2 3 4 Hae III H 1 2 3 4 Hae III
nephrin gene/intron genotyping
Water dilution Wild type mouse DNA dilution
H 1 2 3 4 Hae III H 1 2 3 4 Hae III
hDTR gene genotyping
Figure 6.13: Spiking of the potentially transgenic mice DNA with pIN DNA
H = water control 1 = 0.01 ng/ul 2 = 0.001 ng/ul
3 = 0.0001 ng/ul 4 = 0.00001 ng/ul
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Measurement of genomic copies of the potentially transgenic mice
DNA and pIN copies used in PCR
1. measurement of pIN copies
From the results of genotyping primers PCRs on a dilution series of pIN
DNA in the order 10 ng/ul, 1 ng/ul, 0.1 ng/ul, 0.01 ng/ul, 0.001 ng/ul and
0.0001 ng/ul, it has been found that PCRs gave positive result with 0.0001
ng/ul (figure 6.7). 2 ul from this dilution was used for the PCR, so the amount
used was 0.0002 ng (2X10"13 g). The average concentration of the potentially
transgenic mice DNA was 200 ng/ul, the amount used for PCR was 400 ng
(4X108).
... pIN = 6617 bp
... Molecular weight of bp = 629 Dalton
.'. Molecular weight of pIN = 6617 X 629 = 4X105 Dalton
... Avogadro number (6X1023) = 400,000 g
.'. X (pIN copies used in PCR) = 2X10"13 g
.'. pIN copies = 6X1023X 2X10"13
4X105
=3X105 = 300,000 copies
2. measurement ofmouse genomic copies
... Mouse genome = 2.9X109 bp
... Molecular weight of bp = 629 Dalton
.'. Molecular weight of Mouse genome = 2.9X109 X 629 = 1.8X1012 Dalton
... Avogadro number (6X1023) = 1.8X1012 g
.'. X (mice genomic copies used in PCR) = 4X10 8 g
.'. mice genomic copies = 6X1023X 4X10 8
1.8X1012
= 13X103= 13,000 copies
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Sensitivity of genotyping PCRs
The sensitivity of both genotyping PCRs was measured because from the last result
the number of pIN copies was much greater than mice genomic copies. A dilution
series of pIN DNA in the order 1X10"1 ng/ul, 1X10 2 ng/ul, 1X10"3 ng/ul, 1X1CT4
ng/ul, 1X10"5 ng/ul, 1X10"6 ng/ul, 1X10 7 ng/ul, 1X1CT8 ng/ul, 1X10"9 ng/ul was used
to do both PCRs. The results showed that genotyping PCRs can work on 3000 copies
of pIN DNA (lane 5 in figure 6.14) and because 13,000 copies of murine genomic
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hDTR gene genotyping
Figure 6.14: Sensitivity of genotyping PCRs
1 = 1X10"1 ng/ul
2 = 1X102 ng/ul
3 = 1X10"3 ng/ul
4 = 1X10"4 ng/ul
5 = 1X10"5 ng/ul
6 = 1X10"6 ng/ul
7 = 1X10"7 ng/ul
8 = 1X10-8 ng/ul
9 = 1X10"9 ng/ul
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Southern blotting hybridization of the potentially transgenic mice
DNA
This was done after all of the above genotyping results were negative. Both
genotyping PCRs and their positive controls (PCRs of figure 6.14) were blotted and
hybridized with p32 radiolabeled probes (products of figure 6.14 PCRs). The results
showed negative results for 16 samples of the potentially transgenic mice DNA (all
69 were negative) and positive bands in the positive control (figure 6.15).
The potentially transgenic mice DNA Control PCR
PIN PCR I gDNAs PIN PCR I Plasmid 1 = 1X10 ' n§/ul
y 2 = 1X10"2 ng/ul' ' 3 = 1X10"3 ng/ul
4 = 1X10"4 ng/ul
5 = 1X10"5 ng/ul
6 = 1X10"6 ng/ul
7 = 1X10"7 ng/ul
8 = 1X10"8 ng/ul
9 = 1X10"9 ng/ul
H + -1 16 Hae H 1 2 3 4 5 6 7 8 9 Hae III
nephrin gene/intron genotyping
The potentially transgenic mice DNA Control PCR
y PIN PCR2 gDNAs PIN PCR2 Plasmid 1 = 1X10"1 ng/ul' 2= 1X102 ng/ul
3 = 1X10 3 ng/ul
4 = 1X10"4 ng/ul
• «* 5 = 1X1CT5 ng/ul
6 = 1X10"6 ng/ul
7 = 1X10 7 ng/ul
8 = 1X1CT8 ng/ul
9 = 1X10"9 ng/ul
H + -1 16 Hae H12345678 9Hae III
hDTR gene genotyping
Figure 6.15: Southern blotting hybridization of the potentially transgenic mice
DNA
H = Water control + = Positive control (pIN DNA)
- = Negative control (wild type mouse DNA)
1-16 = the potentially transgenic mice DNA
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Second microinjection trial proved the effectives of the technique:
four transgenic founders were established
Sixty eight founders were generated by the second set of microinjections. Two
genotyping PCRs (nephrin gene/intron and hDTR gene) were done on 66 purified
potentially transgenic mice DNA (2 pups were died). The results showed positive
bands in the founders; tg21.1, tg47.1, tg57.1 and tg65.1 (figure 6.16). So, four hDTR
transgenic founders were established.
123 DNA 123 DNA
nephrin gene/intron genotyping hDTR gene genotyping
Figure 6.16: Genotyping PCRs of the transgenic founders
1 = Hae III 2 = Water control
3 = Positive control (pIN DNA)
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Genotyping PCRs of phase 1 of tg21.1 offspring
Seventeen pups were produced from tg21.1 line. Two genotyping PCRs (nephrin
gene/intron and hDTR gene) were done on 17 purified potentially transgenic mice
DNA. The results showed positive bands in the samples; tg21.1.2, tg21.1.9 and
tg21.1.15 (figure 6.17).
nephrin gene/intron genotyping
+ H 1 2 3 Hae III
hDTR gene genotyping
Figure 6.17: Genotyping PCRs of phase 1 of tg21.1 offspring
+ = Positive control (pIN DNA)
H = Water control
1 =tg21.1.2
2 = tg21.1 9
3 = tg21.1.15
138
Genotyping PCRs of phase 1 of tg47.1 offspring
Seventeen pups were produced from tg47.1 line. Two genotyping PCRs (nephrin
gene/intron and hDTR gene) were done on 17 purified potentially transgenic mice





Figure 6.18: Genotyping PCRs of phase 1 of tg47.1 offspring
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Genotyping PCRs of phase 1 of tg57.1 offspring
Nine pups were produced from tg57.1 line. Two genotyping PCRs (nephrin
gene/intron and hDTR gene) were done on 9 purified potentially transgenic mice
DNA. The results showed positive bands in the samples; tg57.1.36, tg57.1.37,
tg57.1.38, tg57.1.39 and tg57.1.43 (figure 6.19).
1 2 3 4 5 Hae III
nephrin gene/intron genotyping
1 2 3 4 5 Hae III
hDTR gene genotyping







Genotyping PCRs of phase 1 of tg65.1 offspring
Eight pups were produced from tg65.1 line. Two genotyping PCRs (nephrin
gene/intron and hDTR gene) were done on 8 purified potentially transgenic mice





Figure 6.20: Genotyping PCRs of phase 1 of tg65.1 offspring
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Discussion
It was proposed to generate transgenic mice expressing hDTR on podocytes and
study the podocyte injury, glomerular injury and renal outcome after the application
of DT. This was described in hepatocytes by Saito and colleagues (2001) using a
construct (pMS7) with hepatocyte-specific promoter (murine albumin promoter) and
hHB-EGF cDNA (hDTR gene).
The construct pMS7 which was used by the above group to induce hepatocyte injury
with DT was obtained and tested with different restriction enzymes according to its
restriction map, but the size of some bands was not as expected from the map (figure
6.1 and figure 6.2). This was clarified later when the pIN construct was produced and
fully sequenced. This sequencing showed that some restriction sites were not
included in the plasmid pMS7 map.
The construct pMS7 was sequenced with M13For and M13Rev primers following
the restriction enzyme analyses which proved that the correct construct has been
obtained although the map was inaccurate.
It was decided to use the primers; NphslPE.fwd: 5-agg tct aga ggt gag agg ttt gta g-
3V and NphslPE.rev: 5-act gtg get tcc tta gct-3v (with added NotI and BamHI
restriction sites which are essential for the nephrin gene fragment subcloning into
pMS7 and production of podocyte construct) used by Moeller and colleagues (2002).
This was because of its murine origin, size and because they had found that it could
drive total expression of P galactosidase in podocytes.
Nephrin gene fragment PCR was performed with Taq DNA and Vent DNA
polymerases. Taq DNA polymerase PCR was done because it is efficient and easy to
optimize the conditions and it was done in two steps; the first step was with
MONPHSF1 primer, MONPHSBamREV primer (contains BamHI restriction site)
and wild type mouse DNA. The second step was done with MONPHSNotF2 primers
(contains NotI restriction site), MONPHSBamREV primer and the product of the
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first step PCR as a template. The second step was done to introduce the NotI
restriction in the nephrin gene fragment. Once this PCR has been proved to work
Vent DNA polymerase PCR was performed using MONPHSNotF2 primers,
MONPHSBamREV primer and first Taq DNA polymerase PCR product as a
template because of its lower insertion error and to produce blunt ended PCR
product.
This blunt nephrin gene fragment was subcloned into pCR®4Blunt-Topo and
pCR4BN was produced and its midiprepation DNA was sent for sequencing which
showed correct nephrin fragment sequencing. The other advantage of this subcloning
of PCR product besides sequencing it increases the efficiency of this fragment
subcloning at the time of podocyte construct production which is better from plasmid
to plasmid than direct PCR product subcloning into plasmid.
The Podocyte construct; pIN was produced by subcloning of nephrin gene fragment
from pCR4BN into pMS7 and at this stage the construct contains podocyte promoter
and hDTR gene. The construct was ready for murine fertilized ova microinjection but
detailed sequencing showed that there was a translation initiation codon (ATG) at the
BamHI site in the nephrin gene fragment as well as hHB-EGF cDNA. Although
there was a chance of hHB-EGF cDNA translation initiation codon to get work after
murine fertilized ova microinjection it may not.
So, we did not want to explore that after the microinjection and another Vent
polymerase PCR was performed to destroy this codon using MONPHSNotF2 primer,
MonephBamRev2 and pIN DNA as a template. This was successful and the whole
process was repeated till the podocyte construct was ready for the microinjection for
the second time.
Sixty nine pups were generated with microinjection of the male pronucleus. At the
age of 3 weeks they were genotyped by two different PCRs. It was expected to get
10% (7 pups) positive for genotyping PCRs according to Moeller paper (2002). They
reported 12 out of 134 pups were positive for the genotyping PCR (9%). Brinster and
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colleagues (1985) reported that 25% of the founders can be test positive for the
transgene when a few hundred copies of the linear construct were microinjected in
the male pronucleus of the murine fertilized ova. Unfortunately all of the 69 mice
were negative for both genotyping PCRs.
Several steps were undertaken to investigate whether my detection techniques were
adequate, but the results did not change with different annealing temperature, low
magnesium concentration and 40 cycles.
The amount of DNA was proved to be enough when the control PCR was positive
for all of the 69 samples and the primers have shown to be enough to get the PCRs to
work and did not consumed with those multiple bands when the potentially
transgenic mice DNA was spiked with pIN DNA. Also there was no difference in
pIN PCRs when diluted with water or the potentially transgenic mice DNA (figure
6.13).
The genomic copies of the potentially transgenic mice DNA and pIN copies used in
genotyping PCRs were 13,000 and 300,000 copies and this may argued as
insufficient mice genomic copies for PCRs, but the genotyping PCRs sensitivity was
measured and found 3000 copies of pIN DNA. So, the 13,000 genomic copies of
mice DNA were enough for sensitive genotyping PCRs.
The last step was to do southern blotting hybridization and this also was negative for
all of the 69 potentially transgenic mice. At this stage the results were proved to be
negative and another trial of murine fertilized ova microinjection took place with the
podocyte construct at Edinburgh Royal Infirmary.
Sixty eight pups were generated this time with male pronuclear microinjection of the
murine fertilized ova. At the age of 3 weeks 66 of them (two died) were genotyped
by both genotyping PCRs. Four hDTR transgenic founders were established by
giving identical results for both genotyping PCRs.
144
The transgenic lines; tg21.1, tg47.1, tg57.1 and tg65.1 were set to breed with wild
type mice to preserve the lines and enable testing with DT.
The analysis of phase one of the transgenic lines shows that all of the four founders
passed the transgene to their offspring; hence 3 of 17 were positive in tg21.1 line, 1
of 17 in tg47.1 line, 5 of 9 in tg57.1 line and 1 of 8 in tg65.1 line.
The tg21.1 and tg57.1 founders were stopped from breeding and preserved but tg47.1
and tg65.1 lines were continued to breed because the number of their positive
offspring is not enough to be tested histologically for podocytes expression of hDTR.
In tg21.1 line two positive offspring were set to breed with wild type mice. The third
positive mice and one wild (control) were planned to be tested for the expression of
hDTR by anti-hEGF antibody staining of their kidneys. In the tg57.1 line two mice
were set to breed with wild type mice and three were planned for a histopathology
staining as well as one wild type mouse (control).
If the anti-hEGF antibody staining was restricted to podocytes the next step is to test
other tissues for the receptor expression. So, the ideal line will be the one which
expresses the receptor specifically on podocytes. Once this line has been fixed then
DT can be applied.
I would like to mention that since this project was designed in 2001, two models of
specific podocyte injury were published. Matsusaka and colleagues (2005) generated
transgenic mice expressing human CD25 on podocytes and induced their injury by
anti-Tac (Fv)-PE38 (LMB2). Murine nephrin promoter was used to direct the
expression of human CD25. Wharram and associates (2005) reported the generation
of transgenic rats expressing hDTR on podocytes. They used human podocin gene






The renal glomerulus is a highly specialised structure which is responsible for blood
filtration, and while extra fluid is allowed to pass in the glomerular filtrate; larger
proteins are retained. Glomerular filtration occurs through the filtration slits which
are formed between the interdigitation of podocytes foot processes around the GBM.
Podocytes form by an extension of a pre-existing epithelial sheet during
embryogenesis by a process known as branching morphogenesis. In man
metanephric development begins during the fifth week of gestation. It is
characterised by aggregation of nephrogenic mesenchyme opposite to branches of
the ureteral bud (vesicle stage), formation of the primitive S body consisting of
presumptive glomerular and tubular epithelium, followed sequentially by capillary
ingrowth, GBM formation, and differentiation of glomerular visceral (podocytes),
parietal and tubular epithelium (Piatt et al., 1983).
The podocyte can be divided into three structural parts which are; cell body, major
processes and foot processes. Cell bodies and major processes are not attached to the
GBM and float freely in the Bowman's space, leaving a sub-cell body space between
the cell body and the foot processes. Major processes arise directly or after additional
branching from the cell body and split into foot processes (Mundel and Kriz, 1995;
Kriz et al., 1998).
Podocytes have many functions including GBM-turnover, maintenance of the
filtration barrier, capillary tuft support, and regulation of glomerular filtration.
It has been concluded regarding podocytes replication that, the differentiated
podocytes could undergo mitosis but not complete cell division as manifested by bi-
nuclear or multinuclear cells (Pabst and Sterzel, 1983; Rasch and Norgaard, 1983;
Schwartz and Lewis, 1985). In contrast to that, de-differentiated podocytes could
proliferate and this may lead to the development of pseudocrescent formation and
glomerular compression in HIV nephropathy and idiopathic collapsing nephropathy
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(Barisoni et al., 1999; Barisoni et al., 2000). De-differentiated podocytes can also be
grown in culture from rats urine with experimental membranous nephropathy
(Petermann et al 2003) and experimental diabetic nephropathy
(Petermann et al 2004).
Podocyte injury is manifested by proteinuria and leads to the development of
glomerulosclerosis and loss of glomerular function. Podocyte injury is associated
with morphological changes including foot process effacement, cell body
attenuation, and detachment from glomerular basement membrane (Pavenstadt et al.,
2003).
Several forms of inherited proteinuria have been reported due to podocytes proteins
genes mutations. They include Finnish type nephrotic syndrome (Kestila et al.,
1998), congenital nephrotic syndrome (Shih et al., 1999), autosomal recessive FSGS
(Boute et al., 2000), autosomal dominant FSGS (Kaplan et al., 2000) and primary
steroid-resistant FSGS (Denamur et al., 2000).
Some investigators have reported that podocytes can be detected in the urine of
patients with renal disease with immunofluorescence using anti-podocalyxin
antibody. They presented this immunofluorescence technique as a potential non¬
invasive diagnostic tool for renal diseases (Hara et al., 1995; Hara et al., 1998).
The first aim of this project was to investigate the possibility of developing a non¬
invasive diagnostic and predictive technique by detecting urinary podocyte in a non¬
selective group of outpatients with proteinuria (urine protein >+++) which may
replace or decrease the need for renal biopsy. The method of RT-PCR was proposed
to be used to detect the mRNA of nephrin and podocalyxin (podocyte-specific
mRNAs). Li and colleagues (2001) showed that this method can be used in the
diagnosis of acute renal allograft rejection by detecting perforin and granzyme B
mRNA in the urine of these patients.
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This method was fully optimized in a clinically applicable way and proved to be
quite sensitive, but all of patients tested with this method were negative for urinary
podocyte specific mRNAs, although P-actin cDNA PCR (control) was positive in
many samples.
In retrospect, it would have been useful to collect patient data in order to ensure that
high risk patients such as patients with FSGS were included in the study as the
literature suggests that such patients have the highest risk of exhibiting podocyturia.
It was argued that the persistent negativity of this study might be due to podocyte
mRNAs degradation in the urinary bladder or in the outpatient department or because
of podocytes were not present in the urine samples. This has lead to the conclusion
that, this method did not appear to be useful as a diagnostic investigation for
proteinuric renal patients.
It is very important to mention that the storage of non-isotonic urine in the outpatient
department at room temperature for varying periods of time could have adversely
affected cell survival and the findings of subsequent analyses.
Despite the negative results of patients urine samples many results were recorded
during the optimization. It has been recorded that; TRIzol is better than Agilent total
RNA isolation mini kit for total RNA extraction, glycogen and tRNA are similar for
total RNA precipitation, DNasel works better in AMV-RT buffer than MMLV-RT
buffer, P-actin and podocalyxin cDNA primers work on human genomic DNA but
nephrin do not, DNasel kills all DNA in the RNA preparation, and heat completely
destroys DNasel .The PCR is sensitive enough for P-actin and podocalyxin.
In a parallel study urinary podocytes were investigated in another group of 100
patients with similar criteria by an immunofluorescence technique using podocyte-
specific antibody. But when I looked at the literature I discovered that most of the
evidence came from Hara group using the same anti-podocalyxin antibody. So,
several podocyte-specific antibodies were mooted and finally anti-synaptopodin and
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anti-CD2AP antibodies were tested on human kidney sections. Anti-synaptopodin
showed podocyte-specific staining and it was decided it should be used for urinary
sediment staining. The other objective of this study was to test the validity of
immunofluorescence as a non-invasive diagnostic and predictive technique in clinical
practice. Although this has been already reported by Hara group, it was aimed to test
this method with a commercially available antibody.
Only 1% of proteinuric renal patients urine samples stained positive for podocytes
with anti-synaptopodin antibody. Although at this stage the immunofluorescence
results suggested that the negative results of RT-PCR study were negative because
there were no podocytes, the immunofluorescence technique efficiency could be
criticised.
Control experiments were performed on human cultured podocytes to test the RT-
PCR method and immunofluorescence technique used in the above two studies
(using the same methods in chapter 3 and chapter 4). This was a collaboration
between our group and the renal unit at Southmead Hospital in Bristol, where in vitro
culture of differentiated human podocytes was established.
An irrelevant isotype control primary antibody was not employed to determine the
specificity of staining in the immunofluorescence studies and this is an important
caveat in the interpretation of the findings presented
The immunofluorescence control experiment proved that this technique does work,
but does not detect more than 20% of the actual number of podocytes in the urine
and control cells (HeLa cells).
It has been noticed that the pattern of immunofluorescence staining and morphology
change when cells go through cytospin machine. By looking at AB-NT podocytes
(figure 5.1) and HeLa cells (figure 4.5) on coverslips a well defined cell shape and
immunofluorescence staining can be seen which changes after the cytospin (figure
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5.2 and figure 5.3). This was similar to the immunofluorescence pattern of the only
podocyte detected by anti-synaptopodin antibody from patient urine (figure 4.8)
These results contrast with those reported by Hara group. This could be partly
because they examined selected high risk patients, but it may also be relevant that
podocalyxin can be found on platelets among other cells. I looked at a clinically
relevant population using clinically applicable tests. I did not find evidence that
urinary podocyte excretion commonly occurs at detectable levels in these patients.
The immunofluorescence method is similar to the method used in the original paper
by Hara and colleagues (1995), which described urinary podocytes in renal patients,
and in the following papers by the same group; they could be criticised about the
actual number of podocytes they described in their publication and the correlations
they made between urinary podocyte numbers and renal disease severity as well as
correlation with different drugs.
No final conclusion has been obtained for the control experiment of RT-PCR method
at the time ofwriting this thesis due to the presumed contamination.
The second aim of this project was to induce graded podocyte injury with DT in a
transgenic mice model expressing hDTR specifically on podocytes and study the
effects on podocyte structure, glomerular structure and renal outcome.
Specific cell ablation with DT in transgenic mice models expressing hDTR have
been successfully described in hepatocytes (Saito et al., 2001) and macrophages
(Cailhier et al., 2005). hDTR is 1000 fold sensitive than mouse DTR to the effects of
DT.
The generation of transgenic mice expressing hDTR specifically on podocytes was
achieved by microinjection of murine fertilized ova with the plasmid pIN which
contains podocyte specific promoter and hDTR gene.
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The plasmid pIN; the podocyte-specific construct was produced by the substitution
of murine albumin promoter in the plasmid pMS7 (Saito et al., 2001) by murine
nephrin gene fragment (Moeller et al., 2002).
Some unavoidable delay in this arm of the project occurred due to production of a
podocyte constmct with two translation initiation codons and when the first trial of
microinjection did not generate any transgenic founders.
When genotyping PCRs of the potential transgenic mice produced by the first
microinjection set were negative, several steps were undertaken to investigate
whether my detection techniques were adequate, but the results did not change with
different annealing temperature, low magnesium concentration and 40 cycles. The
amount of DNA was proved to be enough, and the primers have shown to be enough
to get the PCRs to work. Also there was no difference in pIN PCRs when diluted
with water or the potentially transgenic mice DNA. The genotyping PCRs were
found sensitive. The southern blotting hybridization was negative.
The second trial of microinjection has established four hDTR transgenic founders
(tg21.1, tg47.1, tg57.1, tg65.1) which have passed the transgene to their phase 1
offspring. Two lines (tg21.1 and tg57.1) will be tested histologically for the
expression of hDTR with anti-hEGF antibody shortly and the other two lines (tg21.1




1. Looking for urinary podocytes is not a clinically useful technique in patients
with proteinuria.
2. The podocyte construct (pIN) has proved its validity by generating four
hDTR transgenic founders by male pronuclear microinjection and
furthermore, all of them have passed the transgene to their offspring.
Further work
1. Investigation of the transgenic mice for the specific expression of hDTR on
their podocytes. This is can be achieved by dual staining of transgenic mice
kidneys with anti-hEGF and anti-synaptopodin antibodies. If this was
successful staining of the other tissues of transgenic mice with anti-hEGF
antibody should follow.
2. If an ideal transgenic line (which expressing hDTR specifically on podocytes)
was established, a graded podocyte injury can be induced with DT and the
consequences in terms of proteinuria, podocyte structure, glomerular
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